

---

## BIOGRAPHICAL SKETCH

---

NAME: **Pierre RONCO**

---

eRA COMMONS USER NAME: RONCO

---

POSITION TITLE: **Emeritus Professor of Nephrology, Sorbonne Université, (French) Académie nationale de médecine and Institut Universitaire de France**

---

EDUCATION/TRAINING: *Baccalauréat 1968, Medical Faculty Saint -Antoine, Université Pierre et Marie Curie (Paris 6)*

---

| INSTITUTION AND LOCATION                                 | DEGREE | Start Date | Completion Date | FIELD OF STUDY |
|----------------------------------------------------------|--------|------------|-----------------|----------------|
| Université Pierre & Marie Curie, now Sorbonne Université | MD     | NA         | 07/1980         | Medicine       |
| Université Paris 7, Denis Diderot and Pasteur Institute  | PhD    | 09/1977    | 07/1980         | Immunology     |

### A. Personal Statement

My clinical and research activities have focused on the care of patients with glomerular disease and the elucidation of the underlying pathophysiological mechanisms. As Head of the Renal Division (1995–2018) and Director of the INSERM Kidney Research Unit (1998–2018) at Tenon Hospital in Paris, I was able to foster an environment highly conducive to teaching and practicing translational nephrology. Over these years, I have mentored an entire generation of clinical investigators, three of whom have attained full professorships in Paris. In recognition of my contributions to training, I received a Doctorate Honoris Causa from Louvain Catholic University for mentoring more than 20 fellows from Belgium, most of whom now hold leadership positions in universities or major clinical institutions in their country. Additionally, I have trained 20 postdoctoral researchers from Japan, China, Europe, and Maghreban countries, all of whom currently occupy faculty or research positions worldwide.

This supportive environment also allowed me to host several Visiting Professors, including Daniel MURUVE (2016), who became Chief of the Nephrology Department at the University of Calgary Medical Center (Canada), and Bob ATKINS (former President of the International Society of Nephrology) and Prue HILL from the University of Sydney (2011–2012).

My group's major contributions to clinical science, kidney immunopathology, and rare kidney diseases have been driven by a close, bidirectional exchange between the clinical division and the research unit. Such collaborations enabled us to:

- Identify the first antigen, neutral endopeptidase, involved in a rare subset of neonatal membranous nephropathy, paving the way for the identification of PLA2R, the major antigen in adult membranous nephropathy.
- Discover a new mechanism of maternal-fetal alloimmunization targeting the kidney, expanding beyond previously known incompatibilities involving red blood cells (Rhesus) and platelets.
- Demonstrate the role of a food antigen, bovine serum albumin, in glomerular disease.
- Characterize a new syndrome linked to mutations in the  $\alpha 1$  chain of type IV collagen (COL4A1), which we named HANAC (Hereditary Angiopathy with Nephropathy, Aneurysms, and muscular Cramps).

In collaboration with investigators from the Mayo Clinic, we further identified three antigens in pediatric (Semaphorin 3B) and adult membranous nephropathy (NELL-1 and PCDH-7), as well as two biomarkers, Exostosins 1 & 2, specific to lupus membranous nephropathy. Together with Arkana Lab (Little Rock) and

Cliniques Saint-Luc in Brussels, we also identified cubilin and amnionless as new antigens in a rare autoimmune disease affecting the proximal tubule.

These advances were made possible by a combination of factors: the large recruitment of patients with rare kidney diseases at Tenon Hospital, strong national and international collaborations including pediatricians, and the proximity of a highly active research unit with a long tradition of translational research. My combined expertise in clinical care, immunology, and kidney pathology has resulted in over 500 research publications, including in *New England Journal of Medicine* (10), *The Lancet* (2), *Science* (2), the *Journal of Experimental Medicine* (3), the *Journal of Cell Biology* (3), and all major nephrology journals, as well as 30 textbook chapters (Hirsch Index 81, Web of Science).

Owing to my expertise in translational nephrology and commitment to disseminating knowledge at the highest level, the International Society of Nephrology (ISN) invited me to chair or co-chair the Scientific Program Committee for four World Congresses of Nephrology (Madrid, Milan, Cape Town, Mexico). More recently, I was appointed Editor-in-Chief of *Kidney International* (KI) starting January 1, 2018. Under my leadership, the journal's impact factor increased from 8.3 to 12.6, positioning KI as a leading nephrology journal for original research.

My research has been continuously supported by the French National Research Agency, the Foundation for Medical Research, the Foundation for Rare Diseases, and by EU funding, including the prestigious **Advanced Grant of the European Research Council** and grants for collaborative projects (Eunefron, EURenOmics), which enabled the recruitment and mentorship of PhD students and postdoctoral fellows.

## B. Positions and Honors

### Positions

|                   |                                                                                                                       |
|-------------------|-----------------------------------------------------------------------------------------------------------------------|
| 2018-             | Emeritus Professor of Nephrology, Sorbonne Université                                                                 |
| <b>1998- 2018</b> | <b>Director, Inserm Unit UMR_S 1155, <i>Rare and common kidney diseases, matrix remodelling and tissue repair</i></b> |
| <b>1995- 2018</b> | <b>Director, Division of Nephrology and Dialysis, Tenon Hospital, Paris, France</b>                                   |
| 1980- 1986        | Assistant Professor of Nephrology, Dept. of Nephrology, Tenon Hospital (Gabriel Richet)                               |
| 2013-             | President, AURA (Non-profit Association caring 1,500 patients on a dialysis program)                                  |
| 2011-             | Vice-president, <i>French Kidney Foundation</i>                                                                       |
| <b>2007-2009</b>  | <b>President, <i>Francophone Society of Nephrology</i></b>                                                            |

### Fellowships and awards

|             |                                                                                 |
|-------------|---------------------------------------------------------------------------------|
| 2023        | <i>Jean Hamburger Medal</i> , Francophone Society of Nephrology                 |
| 2021        | Chan Woon Cheung Memorial Fund Award Lecture                                    |
| <b>2018</b> | <b>Doctor <i>Honoris Causa</i>, Université Catholique de Louvain</b>            |
| 2016        | Honorary Member, Japanese Society of Nephrology                                 |
| 2016        | ERA-EDTA Award for <i>Outstanding Basic Science Contributions to Nephrology</i> |
| <b>2012</b> | <b>Advanced Grant <i>European Research Council</i></b>                          |
| 2012        | FERA (ERA-EDTA Distinguished fellow)                                            |
| 2012        | <i>Grand Prix de Médecine et de la Recherche Médicale de la Ville de Paris</i>  |
| 2011        | <i>Jean Dausset</i> Award (French Society of Immunology)                        |
| 2011        | <i>Rose Lamarca</i> Award (French Foundation for Medical Research)              |
| 2009        | Medal of the Moroccan Society of Nephrology                                     |
| 2008        | Senior, then Honorary Member, <i>Institut Universitaire de France</i>           |
| <b>2007</b> | <b><i>Jean Hamburger award</i>, International Society of Nephrology</b>         |

### Chair of scientific meetings

|             |                                                                                         |
|-------------|-----------------------------------------------------------------------------------------|
| <b>2022</b> | <b>President, ERA-EDTA Congress, Paris (10,000 Px)</b>                                  |
| 2018        | Co-chair European Rare Kidney Disease Network: Nephropathology Workshop, Paris (150 Px) |
| 2018        | Renal Pathology Society meeting, Paris (150 Px)                                         |
| 2017-2019   | Chair, Theme Glomerulonephritis, World, Congress of Nephrology, Melbourne (8,000 Px)    |
| 2016        | Co-President, 28th Annual meeting of the ERCSG, Montvillargenne, France (120 Px)        |
| 2015-2017   | Co-chair, Scientific Program Committee, World Congress of Nephrology, Mexico (6,000 Px) |

2013-2015 Chair, Scientific Program Committee, World Congress of Nephrology, CapeTown (5000 Px)  
**2012 President, ERA-EDTA Congress, Paris (12,000 Px)**  
 2012-2017 Co-chair, World Kidney Day, *Académie nationale de médecine*, Paris (150 Px)  
 2009 President, Scientific Program Committee, Amgen Symposium, Paris, France (200 Px)  
 2007-2009 Co-chair, SPC, World Congress of Nephrology (ISN/ERA-EDTA), Milan, Italy (10,000 Px)

### **Institutional responsibilities**

#### **International Committees**

2018- CK-Net (China Kidney Network) International Advisory Committee  
 2009-2014 EDTA Inherited Kidney Disorders and Immunopathology Working Groups  
 2009-2016 ISN Forefronts Committee  
 2009- Scientific advisory board, NIH network on rare diseases (NEPTUNE)  
 2009-2014 International Scientific Advisory Board, Dutch Kidney Foundation  
**2008-2011 Clinical Science Committee, American Society of Nephrology**

#### **French Committees**

2013-2018 Research Council, *Foundation for Medical Research*  
 2013-2015 Oversight Committee, *Fondation pour la Recherche Médicale*  
 2012 -2016 Advisory board, *Foundation IHU, Cardiometabolism and Nutrition Institute (ICAN)*  
 2012- CKD REIN Study Scientific Committee  
 2011- Scientific Council *Foundation for Rare Diseases*

### **Evaluation, editorship and reviewing activities**

2018 Peer Review Committee RIHS and RIMLS, Radboud Universiteit, Nijmegen (NL)

#### **Nominations:**

*Young Investigator Award ASN:* A. Greka (Harvard),  
*Jean Hamburger Award ISN:* D. Schlöndorff (NY),  
*Bywaters Award ISN:* Karl Nath (Rochester)

#### **Promotions:**

CJ. He (Chief, Renal Division of Nephrology, ICAN, NY),  
 L. Beck (Associate Professor, Boston Univ.),  
 MB. Stokes (Professor of Pathology, Columbia, NY),  
 K. Kiryluk (Professor, Columbia, NY)

### **Editorship**

2018- **Editor in Chief, Kidney International**  
 2007-2017- Theme Editor 'Glomerular Disease' for Nephrology Dialysis and Transplantation  
 1997-2005 Associate Editor, Kidney International  
 1997-2004 Section Editor, Current Opinion in Nephrology and Hypertension

### **Editorial Boards**

2014- Journal of Kidney Diseases (Zhi-Hong Liu, Hangzhou)  
 2014-2016 Advisory Board of Seminars in Immunopathology  
**2007-2017 Journal of the American Society of Nephrology**  
 2007-.2014 Nephron-Experimental Nephrology  
 2005-2017 Nature Clinical Practice Nephrology/Nature Reviews Nephrology  
 2002-. Clinical and Experimental Nephrology (Japanese Society of Nephrology)

**Reviewing activities:** All Nephrology journals, Science, PNAS, JCI, New England Journal of Medicine

## **C. Contributions to Science**

### **1. Identification of the Angiotensin-2 related idiotypic network**

My laboratory initially focused on the idiotypic antibody network of angiotensin II, one of the most potent vasoconstrictors. In two landmark studies with investigators at Johns Hopkins published in *Science*, we demonstrated that anti-idiotypic antibodies could mimic the structure and biological activity of angiotensin II,

uncovering a previously unrecognized layer of regulation within the renin–angiotensin system. These findings provided a conceptual framework linking immunology and cardiovascular physiology, with enduring implications for our understanding of blood pressure regulation and vascular biology.

1. Garcia KC, Desiderio SV, **Ronco PM**, Verroust PJ, Amzel LM. Recognition of angiotensin II: antibodies at different levels of an idiotypic network are superimposable. *SCIENCE*. 1992 257 :528-31.
2. Garcia KC, **Ronco PM**, Verroust PJ, Brünger AT, Amzel LM. Three-dimensional structure of an angiotensin II-Fab complex at 3 Å: hormone recognition by an anti-idiotypic antibody. *SCIENCE*. 1992 257:502-7.

## 2. Identification of antigens and risk alleles in membranous nephropathy (MN) and immune-mediated podocytopathies: a paradigm of translational medicine

Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults and carries a significant risk of progression to kidney failure. In 2002, we identified neutral endopeptidase (NEP) as the first podocyte antigen responsible for a rare subset of neonatal MN. This discovery represented a major breakthrough, occurring nearly 20 years after Heymann’s identification of megalin/LRP2 in the rat model, at a time when most research groups had ceased the search for a human antigen.

The identification of NEP paved the way for the subsequent discovery of M-type phospholipase A2 receptor (PLA2R) and THSD7A antigens by international teams, which account for 70–80% and 1–5% of primary MN cases, respectively. In parallel, we identified bovine serum albumin as the first food antigen implicated in immune glomerulopathies in children.

For years, the remaining antigens remained elusive until 2019, when, in collaboration with investigators at the Mayo Clinic (Rochester, USA), we identified Exostosin-1 and Exostosin-2 (EXT1/2) and Neural EGF-like-1 (NELL-1) as antigens in lupus and “primary” MN, respectively, as well as Semaphorin 3B in pediatric cases. These discoveries have transformed the diagnosis and management of MN, establishing a new paradigm in translational nephrology.

In addition, we performed the first genome-wide association study (GWAS) in European populations (UK, Netherlands, France) and identified two series of risk alleles in **HLA-DQA1** and **PLA2R1**, the gene encoding the primary target antigen in MN. Using a genetic approach, we further demonstrated that non-coding SNPs in the donor genome are associated with recurrence of MN after kidney transplantation.

Translating these findings to the bedside, we conducted the first clinical trial demonstrating the efficacy of rituximab, an anti-CD20 monoclonal antibody, in achieving both immunological and clinical remission in patients with MN.

Building on these advances in membranous nephropathy, our group extended its focus to immune-mediated podocytopathies. After initially investigating genetic contributions, we served as co-senior investigator on a landmark study led by Dr. Huber in Hamburg, published in the *New England Journal of Medicine*. This study demonstrated that anti-nephrin antibodies are detectable in up to 90% of children with steroid-sensitive nephrotic syndrome, 44% of adults with minimal change disease, and 9% of patients with primary focal segmental glomerulosclerosis (FSGS). These findings expand the spectrum of autoimmune podocytopathies and open new avenues for targeted therapeutic interventions.

1. Debiec H, Guignon V, Mougnot B, Decobert F, Haymann JP, Bensman A, Deschênes G, **Ronco P**. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. *N ENGL J MED*. 2002 ;346 :2053-60.
2. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, **Ronco P**. Early childhood membranous nephropathy due to cationic bovine serum albumin. *N ENGL J MED*. 2011;364:2101-102.
3. Debiec H, **Ronco P**. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. *N ENGL J MED*. 2011; 364:689-90.
4. Stanescu HC, et al. ....**Ronco P\***, Mathieson PW\*, Kleta R\*. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. *N ENGL J MED*. 2011 ;364:616-26. \* **Co-senior author**
5. Dahan K, Debiec H, Plaisier E, et al., ....**Ronco P**. GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. *J AM SOC NEPHROL*. 2017;28:348-358.
6. Hengel FE, et al ....**Ronco P\***, Vivarelli M\*, Gesualdo L\*, Thomas NM\*, Huber T\*. Autoantibodies targeting nephrin in podocytopathies. *N ENGL J MED* 2024;391: 422-433 \* **Co-senior author**

### 3. HANAC: a new genetic syndrome affecting COL4A1

We described a new autosomal dominant syndrome, **Hereditary Angiopathy, Nephropathy, Aneurysms, and Muscle Cramps (HANAC)**, caused by mutations in **COL4A1**, which encodes the  $\alpha 1$  chain of type IV collagen, a key component of basement membranes. Patients with HANAC present with a characteristic constellation of clinical features, including cerebral small vessel disease, retinal tortuosity, muscle cramps, and kidney involvement, which manifests as multiple renal cysts, chronic kidney failure, and occasionally hematuria. Mutations responsible for HANAC localize to the integrin-binding site containing the CB3[IV] fragment of the COL4A1 protein.

To understand the pathogenesis of HANAC, we performed detailed reverse phenotyping by generating genetically modified mice carrying the human mutation. These models allowed us to characterize the molecular and cellular mechanisms underlying kidney, muscle, retinal, and cerebral vascular pathology. Although HANAC is a rare disorder, its study provides important insights into the pathophysiology of more common conditions affecting the same organs, including diabetes, cachexia, and neurovascular diseases.

1. Plaisier E, Gribouval O, Alamowitch S, Mougnot B, Prost C, Verpont MC, Marro B, Desmetre T, Cohen SY, Roullet E, Dracon M, Fardeau M, Van Agtmael T, Kerjaschki D, Antignac C, **Ronco P**. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N ENGL J MED 2007; 357:2687-95.
2. Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agtmael T, Marro B, **Ronco P**. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. NEUROLOGY. 2009 ;73:1873-82
3. Chen Z, Migeon T, Verpont MC, Zaidan M, Sado Y, Kerjaschki D, **Ronco P**, Plaisier E.. HANAC Syndrome Col4a1 Mutation Causes Neonate Glomerular Hyperpermeability and Adult Glomerulocystic Kidney Disease. J AM SOC NEPHROL 2016, 27:1042-54
4. Plaisier E, **Ronco P**. COL4A1-Related Disorders 2009 Jun 25 [updated 2016 Jul 7]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GENE REVIEWS®

### D. Research Support (Last 10 years)

| <i>Project Title</i>                                                                                                                    | <i>Funding source</i>            | <i>Amount (Euros)</i> | <i>Period</i>                                                         | <i>Role of the PI</i>        |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------|-----------------------------------------------------------------------|------------------------------|
| <b>OSAI “ Membranous nephropathy : a model for solving organ-specific auto-immunity”</b>                                                | <b>European Research Council</b> | <b>2 500 000</b>      | <b>From May 1st, 2013 to April 30th, 2019</b>                         | <b>Research coordination</b> |
| MN-Aims “ Molecular dissection of PLA2R1-related membranous nephropathy: towards a portfolio of new clinical biomarkers ”               | National Research Agency (ANR)   | 249 921               | From October 1st, 2017 to November 30th, 2020                         | Research coordination        |
| Genetransnephrose “ Genetic and translational studies in patients with steroid sensitive nephrotic syndrome (SSNS)”                     | National Research Agency (ANR)   | 528 518               | From October 1st, 2016 to September 30th, 2021                        | Research coordination        |
| “Impact of anti-C5 antibody on proteinuria in an in vivo model of membranous nephropathy”                                               | Alexion                          | 222 300               | From December 19 <sup>th</sup> , 2017 to June 18 <sup>th</sup> , 2019 | Research coordination        |
| SeroNegMN “PLA2R-negative membranous nephropathy: antigens, models and patients”                                                        | National Research Agency (ANR)   | 392000                | From October 1st, 2020 to September 30th, 2023                        | Research coordination        |
| AirMN “Dynamics of anti-PLA2R1 and anti-THSD7A antibodies in patients with membranous nephropathy: from early stages to active disease” | National Research Agency (ANR)   | 64900                 | From October 1st, 2020 to September 30th, 2024                        | Partner                      |

I have obtained 2 more grants from the National Research Agency in 2024 (Antibody-mediated primary nephrotic syndrome: a paradigm shift for diagnosis and prognostication (NEPHROSIN) & 2025 (PLA2R1-associated membranous nephropathy: From pathophysiology to new therapies) both as a Partner (ongoing financial negotiation)

## Publications in the *New England Journal of Medicine* (Senior author of 8/10)

1. Hengel FE, Dehde S, Lassé M, et al, **Ronco P\***, Vivarelli M\*, Gesualdo L\*, Tomas NM\*, Huber TB\*; **International Society of Glomerular Disease**. Autoantibodies Targeting Nephritin in Podocytopathies. *N Engl J Med*. **2024**;391:422–433. **\*Co-senior authors**  
*Identified anti-nephritin autoantibodies driving steroid-sensitive nephrotic syndrome, minimal change disease, and selected FSGS; expanded understanding of immune podocytopathies.*
2. Seikrit C, **Ronco P**, Debiec H. Factor H Autoantibodies and Membranous Nephropathy. *N Engl J Med*. **2018**;379:2479–2481.  
*Demonstrated complement dysregulation via factor H autoantibodies, broadening immunopathological insights in membranous nephropathy.*
3. Boyer O, Nevo F, Plaisier E, et al.; **Ronco P**. INF2 Mutations in Charcot–Marie–Tooth Disease with Glomerulopathy. *N Engl J Med*. **2011**;365:2377–2388.  
*Linked peripheral neuropathy and glomerular disease through INF2 mutations, highlighting actin cytoskeleton regulation in podocyte function.*
4. Debiec H, Lefeu F, Kemper MJ, et al.; **Ronco P**. Early-Childhood Membranous Nephropathy due to Cationic Bovine Serum Albumin. *N Engl J Med*. **2011**;364:2101–2110.  
*Proved that exogenous antigens can trigger pediatric membranous nephropathy, clarifying disease mechanisms.*
5. Debiec H, **Ronco P**. PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous Nephropathy. *N Engl J Med*. **2011**;364:689–690.  
*Confirmed pathogenic relevance of anti-PLA2R antibodies and glomerular deposition; reinforced antigen-specific diagnostics.*
6. Stanescu HC, Arcos-Burgos M, Medlar A, et al.; Wetzels J\*, **Ronco P\***, Mathieson P\*, Kleta R\* Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic Membranous Nephropathy. *N Engl J Med*. **2011**;364:616–626. **Co-senior authors**.  
*Established genetic susceptibility alleles underpinning autoimmunity in membranous nephropathy.*
7. Plaisier E, Gribouval O, Alamowitch S, et al.; **Ronco P**. COL4A1 Mutations and HANAC Syndrome. *N Engl J Med*. **2007**;357:2687–2695.  
*Described a novel autosomal dominant syndrome caused by COL4A1 mutations, revealing systemic effects of basement membrane defects.*
8. Jaccard A, Moreau P, Leblond V, et al.; **Ronco P**. High-Dose Melphalan vs Melphalan plus Dexamethasone for AL Amyloidosis. *N Engl J Med*. **2007**;357:1083–1093.  
*Randomized trial informing AL amyloidosis treatment strategies, emphasizing renal involvement.*
9. Debiec H, Guigonis V, Mougenot B, et al.; **Ronco P**. Antenatal Membranous Glomerulonephritis due to Anti–Neutral Endopeptidase Antibodies. *N Engl J Med*. **2002**;346:2053–2060.  
*First identification of a podocyte antigen causing antenatal membranous nephropathy; initiated antigen-based classification.*
10. **Ronco P**, Flahault A. Drug-Induced End-Stage Renal Disease. *N Engl J Med*. **1994**;331:1711–1712.  
*Early analysis highlighting iatrogenic contributions to irreversible kidney failure and long-term outcomes.*

## Ten major publications of a total of 34 in the *Journal of the American Society of Nephrology* (Senior Author of 9/10)

1. Fila M, Debiec H, Perrochia H, et al.; **Ronco P**. Recurrence of Anti-Semaphorin 3B–Mediated Membranous Nephropathy after Kidney Transplantation. *J Am Soc Nephrol*. **2022**;33:503–509.  
*Defined, for the first time, post-transplant recurrence of a specific membranous nephropathy antigen, with direct implications for graft monitoring and patient counseling.*
2. Sethi S, Madden BJ, Debiec H, et al.; **Ronco P**. Protocadherin 7–Associated Membranous Nephropathy. *J Am Soc Nephrol*. **2021**;32:1249–1261.  
*Identified a novel antigenic target, expanding the molecular classification of membranous nephropathy and enabling antigen-based diagnosis.*

3. Sethi S, Madden BJ, Debiec H, et al.; **Ronco P.** Exostosin 1/Exostosin 2–Associated Membranous Nephropathy. *J Am Soc Nephrol.* **2019**;30:1123–1136.  
*Established EXT1/EXT2 as defining antigens of autoimmune membranous nephropathy associated with systemic autoimmunity.*
4. Seitz-Polski B, Debiec H, Rousseau A, et al.; **Ronco P.** PLA2R1 Epitope Spreading Predicts Reduced Likelihood of Remission. *J Am Soc Nephrol.* **2018**;29:401–408.  
*Demonstrated that antibody epitope spreading predicts therapeutic response, providing a basis for precision-guided treatment strategies.*
5. Debiec H, Dossier C, Letouzé E, et al.; **Ronco P.** Transethnic GWAS Identifies Risk Alleles in Pediatric Steroid-Sensitive Nephrotic Syndrome. *J Am Soc Nephrol.* **2018**;29:2000–2013.  
*Identified genetic determinants of disease susceptibility and severity across diverse populations.*
6. Dahan K, Debiec H, Plaisier E, et al.; **GEMRITUX Study Group; Ronco P.** Rituximab for Severe Membranous Nephropathy. *J Am Soc Nephrol.* **2017**;28:348–358.  
*Provided the first controlled evidence supporting rituximab efficacy in severe membranous nephropathy, reshaping international clinical practice.*
7. Bally S, Debiec H, Ponard D, et al.; **Ronco P.** PLA2R-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. *J Am Soc Nephrol.* **2016**;27:3539–3544.  
*Linked innate immune pathway deficiency to autoimmunity in membranous nephropathy, with prognostic implications.*
8. Debiec H, **Ronco P.** Immune Response against PLA2R. *J Am Soc Nephrol.* **2016**;27:1275–1277.  
*Synthesized mechanistic, prognostic, and therapeutic implications of anti-PLA2R autoantibodies.*
9. Chen Z, Migeon T, Verpont MC, et al.; **Ronco P.** COL4A1 Mutations and Glomerular Disease (HANAC Syndrome). *J Am Soc Nephrol.* **2016**;27:1042–1054.  
*Demonstrated developmental and adult glomerular consequences of COL4A1 mutations.*
10. Debiec H, Valayannopoulos V, Boyer O, et al.; **Ronco P.** Allo-Immune Membranous Nephropathy and Enzyme Replacement Therapy. *J Am Soc Nephrol.* **2014**;25:675–680.  
*Identified allo-immune mechanisms in membranous nephropathy caused by enzymotherapy*

## Main Lectures (2020–2025)

*Selected invited, plenary and named lectures (plenary and named lectures in bold)*

---

### 2025

- Visiting Professor, Hong Kong (Department of Nephrology) –Two lectures:  
Membranous nephropathy: a new paradigm in classification, diagnosis and treatment;  
Primary nephrotic syndrome: Is anti-nephrin the new anti-PLA2R?
- Seventh International Meeting with Mayo Clinic, Sardinia – Precision medicine in minimal change disease and primary FSGS
- International Congress of Auto-Immunity, Dresden – Pathogenic antibodies in podocytopathies
- Visiting Professor, Mayo Clinic –Two lectures:  
New advances in immune-mediated podocytopathies;  
Complement and B-cell targeting in membranous nephropathy
- Visiting Professor, Ruijin Hospital & JiaoTong University, Shanghai – Recent advances in membranous nephropathy
- Italian Society of Nephrology, Riccione –Two lectures:  
Complement and B-cell targeting in membranous nephropathy;  
Auto-immune podocytopathies
- ASN Kidney Week, Houston – Membranous nephropathy: New treatments on the horizon

---

### 2024

- The Royal Society of Medicine, London – New antigens and classification of membranous nephropathy
- Congress Immune Pathology & Orphan Diseases, Turin – Pathogenesis of membranous nephropathy
- Johns Hopkins University – Medical Grand Rounds – Membranous Nephropathy: From Heymann nephritis to a multi-antigenic disease
- World Congress of Nephrology, Buenos Aires – Classification and management of membranous nephropathy

- International Summer School of Renal Pathology, Bari – Membranous Nephropathy: A new paradigm in classification, diagnosis and treatment
- University Hospital of Geneva – Grand Rounds – Advances in nephrotic syndrome: from pangenomics to anti-nephrin antibodies
- Italian Society of Nephrology, Riccione –Two lectures:  
The new antigen-driven classification of MN:Therapeutic implications;  
Complement & complement antagonists in MN: Is there a window of opportunity?
- Common Grounds Bologna: Primary nephrotic syndrome: Is anti-nephrin the new anti-PLA2R?
- BANTAO Belgrade: Primary nephrotic syndrome: Is anti-nephrin the new anti-PLA2R?
- Slovenian Society of Nephrology: Primary nephrotic syndrome: Is anti-nephrin the new anti-PLA2R?
- Cologne (Nephrology Department): Primary nephrotic syndrome: Is anti-nephrin the new anti-PLA2R?
- Cologne (Division of Pediatric Nephrology): Membranous Nephropathy: A Model of Translational Medicine

---

## 2023

- World Congress of Nephrology, Bangkok – New antigens and serology-based classification in membranous nephropathy
- ERA-EDTA Congress, Istanbul – Novel insights in Membranous Nephropathy changing clinical practice
- Sixth International Meeting with Mayo Clinic, Sardinia – New advances in minimal change disease
- **PLENARY LECTURE – German Society of Nephrology (DGfN), Berlin** – Membranous Nephropathy: A new paradigm for classification, diagnosis and treatment
- **NAMED LECTURE Jack Wetzels Lecture, Nijmegen** – Twenty years of progress in membranous nephropathy

---

## 2022

- SUNY Downstate – Medical Grand Rounds – Membranous Nephropathy: Anti-PLA2R monitoring and cancer screening
- European Renal Cell Study Group, Limassol – Breaking dogmas in membranous nephropathy
- Onco-Nephrology Controversies, MD Anderson Cancer Center Grand Rounds – Membranous nephropathy: A model of translational medicine
- Lausanne University Hospital – Autoantibodies and treatment in membranous nephropathy
- **PLENARY LECTURE – Lesley Rees Memorial Lecture (IPNA, International Pediatric Nephrology Association)** – Membranous nephropathy: a model of translational medicine
- Mayo Clinic – New antigens and disease reclassification
- Common Grounds Bologna: Advances in membranous nephropathy

---

## 2021

- Columbia University – Medical Grand Rounds – The story that never stops
- **NAMED LECTURE – Paul E. Teshan Lecture, Vanderbilt University** –Membranous nephropathy: A model of translational medicine
- Nephrology Grand Round (Vanderbilt University Medical College): Membranous Nephropathy: The story that never stops
- ERA-EDTA Congress, Berlin – The role of anti-PLA2R monitoring
- Podocyte Meeting, Manchester – New antigens and the podocyte in membranous nephropathy
- **NAMED LECTURE – Chan Woon Cheung Memorial Fund Award Lecture** – Membranous nephropathy: A model of translational medicine
- Hong-Kong Society of Nephrology meeting: Therapeutic advances in membranous nephropathy
- European Society of Pediatric Nephrology Amsterdam – Serum and podocyte markers of membranous nephropathy
- Argentina congress of Nephrology: Update on membranous nephropathy: From pathophysiology to therapy
- Sri Lanka: New advances in diagnosis and treatment of membranous nephropathy

---

## 2020

- 20th Winter School, Prague – Two lectures:  
Membranous nephropathy in patients with cancer;



Kidney involvement in monoclonal gammopathy

- NEPTUNE Meeting, Baltimore – Membranous Nephropathy: An ever-changing concept
- ERA-EDTA Congress – Molecular pathogenesis of Membranous Nephropathy
- Grand round at Northwell Health: Membranous nephropathy: Connecting Pathobiology and Clinical Features
- **NAMED LECTURE – Detlef Schlöndorff Lecture, Mount Sinai** – Membranous The ever-changing concept
- Turkish Society of Nephrology –Membranous Nephropathy: Past, present and future
- Duke University – Medical Grand Rounds – Membranous Nephropathy: The story goes on
- Fourth international Renal Pathology Conference, Warsaw: New advances in Membranous Nephropathy: The story goes on

## Complete list of peer-reviewed publications (1978-2025)

### 2025

1. Fervenza FC, Vargas-Brochero MJ, Debiec H, Madden B, Andrade L, Zand L, **Ronco P**, Sethi S. Mass Spectrometry of Minimal Change Disease and Focal Segmental Glomerulosclerosis. *Kidney Int Rep.* **2025** Oct 11;10(12):4219-4233.
2. Rojas-Rivera JE, Caravaca-Fontán F, van de Logt AE, Sevillano A, Shabaka A, Ávila A, Rabasco C, Cabello V, Ortiz A, Quintana LF, Goicoechea M, Diaz M, **Ronco P**, Wetzels J, Fernández-Juárez G, Praga M. Identification of early predictors of clinical remission in primary membranous nephropathy: a <i>post hoc</i> analysis of the STARMEN trial. *Clin Kidney J.* **2025** Aug 13;18(9):sfaf256.
3. Miran M, Ngo K, Buob D, Debiec H, **Ronco P**, Perry G. Microphysiological Glomerular Filtration Barriers: Current Insights, Innovations, and Future Applications. *Adv Biol (Weinh).* **2025** Sep;9(9):e00108.
4. Habbig S, Debiec H, Chedik M, Stippel DL, Erger F, Lourenço A, Liebau MC, **Ronco P**. Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis. *Kidney Int.* **2025** Aug;108(2):321-327.
5. Barbour SJ, **Ronco P**, Praga M, Fervenza FC, Induruwage D, Zhu B, Debiec H, Fernández-Juárez G, Caravaca-Fontán F, Cattran DC; GEMRITUX, MENTOR and STARMEN investigators. Predicting Remission in Antiphospholipase A2 Receptor Antibody- Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials. *Clin J Am Soc Nephrol.* **2025** Apr 14;20(6):854-865.
6. Shu Y, Huang J, Jiang L, Zhang YM, Wang F, Wang X, Meng LQ, Cheng XY, Liu G, Wang SX, Zhao MH, **Ronco P**, Cui Z. Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis. *Kidney Int.* **2025** Sep;108(3):433-444.
7. Riganati M, Conversano E, Zotta F, Gargiulo A, Antonucci L, Giannini C, Ricci G, Diomedì-Camassei F, Debiec H, **Ronco P**, Emma F, Vivarelli M, Colucci M. Comparison of B lymphocyte profile between membranous nephropathy and idiopathic nephrotic syndrome pediatric patients. *Pediatr Nephrol.* **2025** Aug;40(8):2551-2559.
8. Morelle J, Aydin S, Debiec H, Demoulin N, Dufour I, Martin M, Gatto L, Vertommen D, **Ronco P**. Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy. *Am J Kidney Dis.* **2025** Jul;86(1):63-73.e1.
9. van den Berge BT, van den Broek M, Di Giovanni G, Debiec H, Gloudemans S, Leusink Q, den Braanker D, Wetzels JFM, **Ronco P**, Smeets B, Jansen J, Maas RJ. Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome. *Nephrol Dial Transplant.* **2025** Aug 29;40(9):1736-1745.
10. Hengel FE, Dehde S, Yilmaz A, Bayazit AK, Ozaltin F, Paripovic D, Emma F, **Ronco P**, Vivarelli M, Hogan J, Schaefer F, Tomas NM, Huber TB; PodoNet Consortium and the International Society of Glomerular Disease. Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy. *Kidney Int.* **2025** Jun;107(6):1099-1103.
11. Machalitza M, Debiec H, Krümpelmann B, Ferru N, Kiliclas ME, Huber TB, Reinhard L, Wiech T, **Ronco P**, Hoxha E. PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA2R1- or NELL1-associated membranous nephropathy. *Kidney Int.* **2025** Jan;107(1):188-191.

### 2024

12. Cremoni M, Teisseire M, Thauinat O, Fernandez C, Payre C, Moutou A, Zarif H, Brglez V, Albano L, Moal V, Mourad G, Morelon E, Hurault de Ligny B, Zaoui P, Rondeau E, Ouali N, **Ronco P**, Moulin B, Braun-Parvez L, Durrbach A, Heng AE, Grimbert P, Ducloux D, Blancho G, Merville P, Choukroun G, Le Meur Y, Vigneau C, Mariat C, Rostaing L, Subra JF, Taupin JL, Lambeau G, Esnault V, Sicard A, Seitz-Polski B. Anti Phospholipase A2 Receptor 1 Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation. *Kidney Int Rep.* **2024** Sep 23;9(12):3427-3438.
13. Rovin BH, **Ronco PM**, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. *Kidney Int Rep.* **2024** Jun 20;9(9):2635-2647.
14. Sethi S, Madden B, Casal Moura M, Nasr SH, Alexander MP, Debiec H, Torrel N, Gross L, Negron V, Specks U, Fervenza FC, Haas M, **Ronco P**, Batal I. FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection. *Kidney Int.* **2024** Nov;106(5):985-990.

15. Dolla G, Nicolas S, Dos Santos LR, Bourgeois A, Pardossi-Piquard R, Bihl F, Zaghrini C, Justino J, Payré C, Mansuelle P, Garbers C, **Ronco P**, Checler F, Lambeau G, Petit-Paitel A. Ectodomain shedding of PLA2R1 is mediated by the metalloproteases ADAM10 and ADAM17. *J Biol Chem*. **2024** Jul;300(7):107480.
16. Hengel FE, Dehde S, Lassé M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, **Ronco P**, Vivarelli M, Gesualdo L, Tomas NM, Huber TB; International Society of Glomerular Disease. Autoantibodies Targeting Nephrin in Podocytopathies. *N Engl J Med*. **2024** Aug 1;391(5):422-433.
17. Wong G, Bernier-Jean A, Rovin B, **Ronco P**; Editors of Kidney International. Time for action: recognizing chronic kidney disease as a major noncommunicable disease driver of premature mortality. *Kidney Int*. **2024** Jun;105(6):1144-1146.
18. Garderet L, Ouldjeriouat H, Bekadja MA, Daguenet E, Bigot N, Vincent L, Roos-Weil D, Vignon M, Ikhlef S, Abraham J, Escoffre-Barbe M, Lioure B, Nacer RA, Lafon I, Mariette C, Karlin L, Morel P, Gilis L, Le Ray E, Blouet A, Nguyen Quoc S, Boffa JJ, **Ronco P**, Lambert J, Cornillon J. Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study. *Br J Haematol*. **2024** Apr;204(4):1450-1458.
19. Conversano E, Debiec H, Colucci M, Emma F, **Ronco P**, Vivarelli M. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance. *Pediatr Nephrol*. **2024** Jan;39(1):305-308.
20. De Chiara L, **Ronco P**, Rovin BH. Green nephrology: an editor's journey. *J Nephrol*. **2024** Jan;37(1):3-5.

## 2023

21. Devuyst O, **Ronco P**. Tubular handling of filtered albumin. *Kidney Int*. **2023** Dec;104(6):1073-1075.
22. Sethi S, Beck LH Jr, Glasscock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D'Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D'Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, Lieske JC, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccatello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, **Ronco P**, Fervenza FC. Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. *Mayo Clin Proc*. **2023** Nov;98(11):1671-1684.
23. Sethi S, Beck LH Jr, Glasscock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D'Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D'Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, Lieske JC, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccatello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, **Ronco P**, Fervenza FC. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. *Kidney Int*. **2023** Dec;104(6):1092-1102.
24. Barry A, McNulty MT, Jia X, Gupta Y, Debiec H, Luo Y, Nagano C, Horinouchi T, Jung S, Colucci M, Ahram DF, Mitrotti A, Sinha A, Teeninga N, Jin G, Shril S, Caridi G, Bodria M, Lim TY, Westland R, Zanon F, Marasa M, Turudic D, Giordano M, Gesualdo L, Magistroni R, Pisani I, Fiaccadori E, Reiterova J, Maringhini S, Morello W, Montini G, Weng PL, Scolari F, Saraga M, Tasic V, Santoro D, van Wijk JAE, Milošević D, Kawai Y, Kiryluk K, Pollak MR, Gharavi A, Lin F, Simões E Silva AC, Loos RJJ, Kenny EE, Schreuder MF, Zurowska A, Dossier C, Ariceta G, Drozynska-Duklas M, Hogan J, Jankauskiene A, Hildebrandt F, Prikhodina L, Song K, Bagga A, Cheong H 2nd, Ghiggeri GM, Vachvanichsanong P, Nozu K, Lee D, Vivarelli M, Raychaudhuri S, Tokunaga K, Sanna-Cherchi S, **Ronco P**, Iijima K, Sampson MG. Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome. *Nat Commun*. **2023** Apr 29;14(1):2481.
25. Sethi S, Casal Moura M, Madden B, Debiec H, Nasr SH, Larsen CP, Gross L, Negron V, Singh RD, Nath KA, Storey AJ, Specks U, Fervenza FC, **Ronco P**, Caza TN. Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. *Kidney Int*. **2023** Aug;104(2):343-352.
26. Orozco-Guillén AO, Abraham VS, Moguel Gonzalez B, Valdez Ortiz R, Ibarguengoitia F, Del Carmen ZM, Debiec H, **Ronco P**, Madero M, Piccoli GB. Kidney-Limited Full-House Lupus-like Membranous Nephropathy and Membranoproliferative Glomerulonephritis in Pregnancy. *Kidney Int Rep*. **2023** Jan 16;8(4):932-938.
27. Fernández-Juárez G, **Ronco P**, Jha V. Personalized Treatment of PLA2R-Related Membranous Nephropathy. *Clin J Am Soc Nephrol*. **2023** Apr 1;18(4):530-532.
28. Eikrem Ø, Lillefosse B, Delaleu N, Strauss P, Osman T, Vikse BE, Debiec H, **Ronco P**, Sekulic M, Koch E, Furriol J, Leh SM, Marti HP. Network-Based Assessment of Minimal Change Disease Identifies Glomerular Response to IL-7 and IL-12 Pathways Activation as Innovative Treatment Target. *Biomedicines*. **2023** Jan 16;11(1):226.
29. Zhang XD, Lin CX, Cui Z, Gu QH, Yan BJ, Liu L, Song WC, Shi Y, Debiec H, **Ronco P**, Zhao MH. Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy. *Kidney Int*. **2023** Mar;103(3):580-592.
30. **Ronco P**, Plaisier E, Debiec H. The role of PLA2R antibody monitoring: what we know and what we do not know. *Nephrol Dial Transplant*. **2023** Mar 31;38(4):826-833.
31. Fakhouri F, Schwotzer N, Cabiddu G, Barratt J, Legardeur H, Garovic V, Orozco-Guillen A, Wetzels J, Daugas E, Moroni G, Noris M, Audard V, Praga M, Llurba E, Wuerzner G, Attini R, Desseauve D, Zakharova E, Luders C, Wiles K, Leone F, Jesudason S, Costedoat-Chalumeau N, Kattah A, Soto-Abraham V, Karras A, Prakash J, Lightstone L, **Ronco P**, Ponticelli C, Appel G, Remuzzi G, Tsatsaris V, Piccoli GB. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. *Kidney Int*. **2023** Feb;103(2):264-281.

## 2022

32. Chung EYM, Blazek K, Teixeira-Pinto A, Sharma A, Kim S, Lin Y, Keung K, Bose B, Kairaitis L, McCarthy H, **Ronco P**, Alexander SI, Wong G. Predictive Models for Recurrent Membranous Nephropathy After Kidney Transplantation. *Transplant Direct*. **2022** Aug 4;8(9):e1357.

33. Muruve DA, Debiec H, Dillon ST, Gu X, Plaisier E, Can H, Otu HH, Libermann TA, **Ronco P**. Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy. *Kidney Int Rep*. **2022** Apr 14;7(7):1539-1556.
34. Rovin BH, Boxhammer R, Thakur A, **Ronco PM**. Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study. *Kidney Int Rep*. **2022** Sep;7(9):2086-2090.
35. Santoro D, Debiec H, Longhitano E, Torreggiani M, Barreca A, Vegezzi E, Mazzeo A, Russo M, Piccoli GB, Toscano A, **Ronco P**. Contactin 1, a Potential New Antigen Target in Membranous Nephropathy: A Case Report. *Am J Kidney Dis*. **2022** Aug;80(2):289-294.
36. Torreggiani M, Fois A, Chatrenet A, Nielsen L, Gendrot L, Longhitano E, Lecointre L, Garcia C, Breuer C, Mazé B, Hami A, Seret G, Saulniers P, **Ronco P**, Lavainne F, Piccoli GB. Incremental and Personalized Hemodialysis Start: A New Standard of Care. *Kidney Int Rep*. **2022** Feb 19;7(5):1049-1061.
37. Coates PT, Wong G, Rovin BH, **Ronco P**; Entire Editorial and Management Team. A challenge to the kidney community by a man-made crisis. *Kidney Int*. **2022** May;101(5):854-855.
38. Morelle J, Caza T, Debiec H, Aydin S, Storey A, **Ronco P**, Larsen C. Cubilin and amnionless protein are novel target antigens in anti-brush border antibody disease. *Kidney Int*. **2022** May;101(5):1063-1068.
39. Bomback AS, Appel GB, Gipson DS, Hladunewich MA, Lafayette R, Nester CM, Parikh SV, Smith RJH, Trachtman H, Heeger PS, Ram S, Rovin BH, Ali S, Arceneaux N, Ashoor I, Bailey-Wickins L, Barratt J, Beck L, Cattran DC, Cravedi P, Erkan E, Fervenza F, Frazer-Abel AA, Fremeaux-Bacchi V, Fuller L, Gbadegesin R, Hogan JJ, Kiryluk K, le Quintrec-Donnette M, Licht C, Mahan JD, Pickering MC, Quigg R, Rheault M, **Ronco P**, Sarwal MM, Sethna C, Spino C, Stegall M, Vivarelli M, Feldman DL, Thurman JM. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *Am J Kidney Dis*. **2022** Apr;79(4):570-581.
40. Fila M, Debiec H, Perrochia H, Djouadi N, Verpont MC, Buob D, **Ronco P**. Recurrence of Anti-Semaphorin 3B-Mediated Membranous Nephropathy after Kidney Transplantation. *J Am Soc Nephrol*. **2022** Mar;33(3):503-509.
41. Wetzels JFM, **Ronco P**, Jha V; KDIGO Membranous Nephropathy Working Group. The authors reply. *Kidney Int*. **2022** Jan;101(1):187.
42. Estève E, Buob D, Jamme F, Jouanneau C, Kascakova S, Haymann JP, Letavernier E, Galmiche L, **Ronco P**, Daudon M, Bazin D, Réfrégiers M. Detection and localization of calcium oxalate in kidney using synchrotron deep ultraviolet fluorescence microscopy. *J Synchrotron Radiat*. **2022** Jan 1;29(Pt 1):214-223.

## 2021

43. Plaisier E, Not A, Buob D, **Ronco P**, Debiec H. Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab. *Kidney Int*. **2021** Dec;100(6):1342-1344.
44. Debiec H, **Ronco P**. When contactin antibodies hit the podocyte: a new neurorenal syndrome. *Kidney Int*. **2021** Dec;100(6):1163-1165.
45. **Ronco P**, Plaisier E. Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy? *Clin J Am Soc Nephrol*. **2021** Dec;16(12):1787-1789.
46. **Ronco P**, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M, Wetzels J. Membranous nephropathy. *Nat Rev Dis Primers*. **2021** Sep 30;7(1):69.
47. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glasscock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, **Ronco P**, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. *Kidney Int*. **2021** Oct;100(4):753-779.
48. Aucouturier P, D'Agati VD, **Ronco P**. A Fresh Perspective on Monoclonal Gammopathies of Renal Significance. *Kidney Int Rep*. **2021** May 4;6(8):2059-2065.
49. Nortier JL, Remiche G, Delrée P, Nauta J, Notermans NC, Vivarelli M, Diodato D, Solé G, Debiec H, **Ronco P**. Antenatal Membranous Nephropathy and Type 2 (Axonal) Charcot-Marie-Tooth With Mutations in the Metallo-Membrane Endopeptidase Gene: A Call for Family Screening and Pharmacovigilance. *Kidney Int Rep*. **2021** May 12;6(7):1981-1986.
50. Saïdi M, Brochérou I, Estève E, Tuffet S, Amoura Z, Miyara M, Belenfant X, Ulinski T, Rouvier P, Debiec H, **Ronco P**, Buob D. The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes. *Kidney Int Rep*. **2021** May 5;6(7):1977-1980.
51. Hanset N, **Ronco P**, Plaisier E. Glomérulonéphrite extramembraneuse [Membranous nephropathy]. *Rev Prat*. **2021** Jan;71(1):85-89. French.
52. Berchtold L, Letouzé E, Alexander MP, Canaud G, Logt AV, Hamilton P, Mousson C, Vuiblet V, Moyer AM, Guibert S, Mrázová P, Levi C, Dubois V, Cruzado JM, Torres A, Gandhi MJ, Yousfi N, Tesar V, Viklický O, Hourmant M, Moulin B, Rieu P, Choukroun G, Legendre C, Wetzels J, Brenchley P, Ballarín Castan JA, Debiec H, **Ronco P**. Corrigendum to Berchtold L, Letouzé E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. *Kidney Int*. **2021**;99:671-685. *Kidney Int*. **2021** Jul;100(1):243.
53. Ikizler TA, Coates PT, Rovin BH, **Ronco P**. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. *Kidney Int*. **2021** Jun;99(6):1275-1279.
54. Sethi S, Madden B, Debiec H, Morelle J, Charlesworth MC, Gross L, Negron V, Buob D, Chaudhry S, Jadoul M, Fervenza FC, **Ronco P**. Protocadherin 7-Associated Membranous Nephropathy. *J Am Soc Nephrol*. **2021** May 3;32(5):1249-1261.
55. **Ronco P**, Rovin BH; Entire Editorial and Management Team. Looking back and moving forward. *Kidney Int*. **2021** Apr;99(4):787-790.
56. Dembele M, Delafosse M, Yousfi N, Debiec H, Ngo K, Plaisier E, **Ronco P**, Perry G. Modélisation de la barrière de filtration glomérulaire - Nouvelles avancées [Models of glomerular filtration barrier : New developments]. *Med Sci (Paris)*. **2021** Mar;37(3):242-248. French.
57. **Ronco P**, Plaisier E, Debiec H. Advances in Membranous Nephropathy. *J Clin Med*. **2021** Feb 5;10(4):607.

58. **Ronco P**, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens. *Curr Opin Nephrol Hypertens*. **2021** May 1;30(3):287-293.
59. Bridoux F, Leung N, Belmouaz M, Royal V, **Ronco P**, Nasr SH, Femand JP; International Kidney and Monoclonal Gammopathy Research Group. Management of acute kidney injury in symptomatic multiple myeloma. *Kidney Int*. **2021** Mar;99(3):570-580.
60. Lwezula BF, Ameh OI, Ekrikpo UE, Botha FC, Okpechi-Samuel US, Wearne N, **Ronco P**, Bello AK, Okpechi IG. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans. *BMC Nephrol*. **2021** Jan 7;22(1):15.
61. **Ronco P**, Rovin B, Nangaku M, Wyatt C, Jha V; Associate Editors, for the Entire Editorial Team. Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. *Kidney Int*. **2021** Jan;99(1):2-4.
62. Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez- Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, **Ronco P**, Wetzels J, Praga M; STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. *Kidney Int*. **2021** Apr;99(4):986-998.
63. Berchtold L, Letouze E, Alexander MP, Canaud G, Logt AV, Hamilton P, Mousson C, Vuiblet V, Moyer AM, Guibert S, Mrázová P, Levi C, Dubois V, Cruzado JM, Torres A, Gandhi MJ, Yousfi N, Tesar V, OndrejViklický, Hourmant M, Moulin B, Rieu P, Choukroun G, Legendre C, Wetzels J, Brenchley P, Ballarín Castan JA, Debiec H, **Ronco P**. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. *Kidney Int*. **2021** Mar;99(3):671-685.
64. Kudose S, Santoriello D, Debiec H, Canetta PA, Bombback AS, Stokes MB, Batal I, **Ronco P**, D'Agati VD, Markowitz GS. The clinicopathologic spectrum of segmental membranous glomerulopathy. *Kidney Int*. **2021** Jan;99(1):247-255.

## 2020

65. Sethi S, Nast CC, D'Agati VD, Fervenza FC, Glasscock RJ, Stokes MB, De Vriese AS, Appel GB, Chang A, Cosio F, Herrera Hernandez L, Markowitz GS, Kumar SK, Alexander MP, Amer H, Murray D, Nasr SH, Leung N, Pani A, Picken MM, Ravindran A, Roccatello D, **Ronco P**, Royal V, Smith KD, Wechalekar AD, Wetzels J, Zand L, Zhang P, Haas M. Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. *Kidney Int*. **2020** Aug;98(2):310-313.
66. Hanset N, Aydin S, Demoulin N, Cosyns JP, Castanares-Zapatero D, Crott R, Cambier JF, Pochet JM, Gillerot G, Reginster F, Houssiau F, Debiec H, **Ronco P**, Jadoul M, Morelle J; UCLouvain Kidney Disease Network. Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study. *Am J Kidney Dis*. **2020** Nov;76(5):624-635.
67. Usui J, Yaguchi M, Yamazaki S, Takahashi-Kobayashi M, Kawamura T, Kaneko S, Seshan SV, **Ronco P**, Yamagata K. Transcription factor 21 expression in injured podocytes of glomerular diseases. *Sci Rep*. **2020** Jul 13;10(1):11516.
68. Jia X, Yamamura T, Gbadegesin R, McNulty MT, Song K, Nagano C, Hitomi Y, Lee D, Aiba Y, Khor SS, Ueno K, Kawai Y, Nagasaki M, Noiri E, Horinouchi T, Kaito H, Hamada R, Okamoto T, Kamei K, Kaku Y, Fujimaru R, Tanaka R, Shima Y; Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan; Baek J, Kang HG, Ha IS, Han KH, Yang EM; Korean Consortium of Hereditary Renal Diseases in Children; Abeyagunawardena A, Lane B, Chryst-Stangl M, Esezobor C, Solarin A; Midwest Pediatric Nephrology Consortium (Genetics of Nephrotic Syndrome Study Group); Dossier C, Deschênes G; NEPHROVIR; Vivarelli M, Debiec H, Ishikura K, Matsuo M, Nozu K, **Ronco P**, Cheong HI, Sampson MG, Tokunaga K, Iijima K. Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. *Kidney Int*. **2020** Nov;98(5):1308-1322.
69. Sethi S, Debiec H, Madden B, Vivarelli M, Charlesworth MC, Ravindran A, Gross L, Ulinski T, Buob D, Tran CL, Emma F, Diomedi-Camassee F, Fervenza FC, **Ronco P**. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. *Kidney Int*. **2020** Nov;98(5):1253-1264.
70. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, **Ronco P**, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney Int*. **2020** Jun;97(6):1117-1129.
71. Esteve E, Luque Y, Waeytens J, Bazin D, Mesnard L, Jouanneau C, **Ronco P**, Dazzi A, Daudon M, Deniset-Besseau A. Nanometric Chemical Speciation of Abnormal Deposits in Kidney Biopsy: Infrared-Nanospectroscopy Reveals Heterogeneities within Vancomycin Casts. *Anal Chem*. **2020** Jun 2;92(11):7388-7392.
72. Ravindran A, Madden B, Charlesworth MC, Sharma R, Sethi A, Debiec H, Catran D, Fervenza FC, Smith RJ, **Ronco P**, Sethi S. Proteomic Analysis of Complement Proteins in Membranous Nephropathy. *Kidney Int Rep*. **2020** Jan 30;5(5):618-626.
73. Coates PT, Wong G, Druke T, Rovin B, **Ronco P**; Associate Editors, for the Entire Editorial Team. Early experience with COVID-19 in kidney transplantation. *Kidney Int*. **2020** Jun;97(6):1074-1075.
74. Rovin BH, **Ronco P**; Associate Editors; Entire Editorial Team. Kidney International and the COVID-19 infection. *Kidney Int*. **2020** May;97(5):823.
75. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, Cui Z, Lin L, Hu X, Yu X, Xu J, Liu G, Caliskan Y, Sidore C, Balderes O, Rosen RJ, Bodria M, Zanon F, Zhang JY, Krithivasan P, Mehl K, Marasa M, Khan A, Ozay F, Canetta PA, Bombback AS, Appel GB, Sanna-Cherchi S, Sampson MG, Mariani LH, Perkowska-Ptasinska A, Durlak M, Mucha K, Moszczuk B, Foronczewicz B, Pączek L, Habura I, Ars E, Ballarín J, Mani LY, Vogt B, Ozturk S, Yildiz A, Seyahi N, Arikani H, Koc M, Basturk T, Karahan G, Akgul SU, Sever MS, Zhang D, Santoro D, Bonomini M, Londrino F, Gesualdo L, Reiterova J, Tesar V, Izzi C, Savoldi S, Spotti D, Marcantoni C, Messa P, Galliani M, Roccatello D, Granata S, Zaza G, Lugani F, Ghiggeri G, Pisani I, Allegri L, Sprangers B, Park JH, Cho B, Kim YS, Kim DK, Suzuki H, Amoroso A, Catran DC, Fervenza FC, Pani A, Hamilton

- P, Harris S, Gupta S, Cheshire C, Dufek S, Issler N, Pepper RJ, Connolly J, Powis S, Bockenbauer D, Stanescu HC, Ashman N, Loos RJF, Kenny EE, Wuttke M, Eckardt KU, Köttgen A, Hofstra JM, Coenen MJH, Kiemeny LA, Akilesh S, Kretzler M, Beck LH, Stengel B, Debiec H, **Ronco P**, Wetzels JFM, Zoledziewska M, Cucca F, Ionita-Laza I, Lee H, Hoxha E, Stahl RAK, Brenchley P, Scolari F, Zhao MH, Gharavi AG, Kleta R, Chen N, Kiryluk K. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. *Nat Commun*. **2020** Mar 30;11(1):1600.
76. Lescure FX, Fellahi S, Pialoux G, Bastard JP, Esteve E, Lebrette MG, Guiard-Schmid JB, Capeau J, **Ronco P**, Costagliola D, Plaisier E. Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. *Nephrol Dial Transplant*. **2020** Apr 1;35(4):607-615.
77. Malyszko J, Lee MW, Capasso G, Kulicki P, Matuszkiewicz-Rowinska J, **Ronco P**, Stevens P, Tesarova P, Viggiano D, Capasso A. How to assess kidney function in oncology patients. *Kidney Int*. **2020** May;97(5):894-903.
78. Plaisier E, **Ronco P**. Screening for Cancer in Patients with Glomerular Diseases. *Clin J Am Soc Nephrol*. **2020** Jun 8;15(6):886-888.
79. **Ronco P**. Pathophysiology of the glomerulus: KI tells the story. *Kidney Int*. **2020** Jan;97(1):5-9.
80. **Ronco P**, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. *Annu Rev Pathol*. **2020** Jan 24;15:287-313.
81. Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, Ravindran A, Buob D, Jadoul M, Fervenza FC, **Ronco P**. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. *Kidney Int*. **2020** Jan;97(1):163-174.

## 2019

82. Hanset N, Esteve E, Plaisier E, Johanet C, Michel PA, Boffa JJ, Fievet P, Mesnard L, Morelle J, **Ronco P**, Dahan K. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD. *Kidney Int Rep*. **2019** Dec 20;5(3):331-338.
83. Noël E, Dussol B, Lacombe D, Bedreddine N, Fouilhoux A, **Ronco P**, Genevaz D, Bekri S, Hagège A, Dupuis-Siméon F, Derrien Ansquer V, Germain DP, Lidove O. Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire. *Orphanet J Rare Dis*. **2019** Dec 4;14(1):284.
84. **Ronco P**, Rovin B, Nangaku M, Jha V. Kidney International celebrates the 60th anniversary of the International Society of Nephrology. *Kidney Int*. **2019** Dec;96(6):1248-1249.
85. Dähnrich C, Saschenbrecker S, Gunnarsson I, Schlumberger W, **Ronco P**, Debiec H. Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy. *Kidney Int Rep*. **2019** Nov 22;5(2):182-188.
86. Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, **Ronco P**, Rosner MH, Trepiccone F, Viggiano D, Zoccali C, Capasso G; International Conference on Onco-Nephrology Participants. Summary of the International Conference on Onco- Nephrology: an emerging field in medicine. *Kidney Int*. **2019** Sep;96(3):555-567.
87. Torban E, Braun F, Wanner N, Takano T, Goodyer PR, Lennon R, **Ronco P**, Cybulsky AV, Huber TB. From podocyte biology to novel cures for glomerular disease. *Kidney Int*. **2019** Oct;96(4):850-861.
88. Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, **Ronco P**, Esnault VLM. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. *Clin J Am Soc Nephrol*. **2019** Aug 7;14(8):1173-1182.
89. Georges E, Johanet C, Plaisier E, Debiec H, **Ronco P**, Dahan K. Efficacy of Rituximab in a Patient With Partial Clinical Remission and Persistent Circulating PLA2R-Ab. *Kidney Int Rep*. **2019** Mar 13;4(7):1027-1030.
90. Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC, **Ronco P**. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. *J Am Soc Nephrol*. **2019** Jun;30(6):1123-1136.
91. Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Jais JP, Lillo-Le Louët A, Pontoizeau C, Cochat P, Bataille P, Bridoux F, Brignon P, Choquet C, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Frimat M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N'Guyen HV, Normand M, Pietak M, **Ronco P**, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M; French Cystinuria Group. Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. *BJU Int*. **2019** Nov;124(5):849-861.
92. Veyrat M, Fessi H, Haymann JP, **Ronco P**, Lacau St Guily J, Périé S. Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism. *Eur Ann Otorhinolaryngol Head Neck Dis*. **2019** Apr;136(2):63-68.
93. Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, **Ronco P**, Debiec H, Lambeau G. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. *Kidney Int*. **2019** Mar;95(3):666-679.
94. **Ronco P**, Rovin B; Associate Editors; Entire Editorial Team. Citius, altius, fortius . . . faster, higher, stronger. *Kidney Int*. **2019** Mar;95(3):476-478.
95. Bastard JP, Fellahi S, Regeniter A, Capeau J, **Ronco P**, Plaisier E. Aside from acute renal failure cases, are urinary markers of glomerular and tubular function useful in clinical practice? *Clin Biochem*. **2019** Mar;65:1-6.
96. Dahan K, Johanet C, Esteve E, Plaisier E, Debiec H, **Ronco P**. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. *Kidney Int*. **2019** Jan;95(1):233-234.

## 2018

97. Seikrit C, **Ronco P**, Debiec H. Factor H Autoantibodies and Membranous Nephropathy. *N Engl J Med*. **2018** Dec 20;379(25):2479-2481.
98. Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, Delmas Y, Le Quintrec M, Guerrot D, Jourde-Chiche N, Ribes D, **Ronco P**, Bridoux F, Fremeaux-Bacchi V. Both Monoclonal and Polyclonal Immunoglobulin

Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. *Front Immunol.* **2018** Oct 2;9:2260.

99. van de Logt AE, Dahan K, **Ronco P**, Wetzels J. The authors reply. *Kidney Int.* **2018** Oct;94(4):830.
100. Sethi S, Dasari S, Plaisier E, **Ronco P**, Nasr SH, Brocheriou I, Theis JD, Vrana JA, Zimmermann MT, Quint PS, McPhail ED, Kurtin PJ. Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation. *Kidney Int Rep.* **2018** Apr 22;3(5):1193-1201.
101. Wang HY, Cui Z, Xie LJ, Zhang LJ, Pei ZY, Chen FJ, Qu Z, Huang J, Zhang YM, Wang X, Wang F, Meng LQ, Cheng XY, Liu G, Zhou XJ, Zhang H, Debiec H, **Ronco P**, Zhao MH. HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy. *Kidney Int.* **2018** Nov;94(5):974-982.
102. Harris D, Wyatt CM, Fogo AB, **Ronco P**. The Bowman's shield: a tribute to translational science and Detlef Schlöndorff. *Kidney Int.* **2018** Sep;94(3):448-450.
103. Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschênes G, **Ronco P**. Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. *J Am Soc Nephrol.* **2018** Jul;29(7):2000-2013.
104. **Ronco P**. Gabriel Richet: when medicine combines with courage. *BMC Nephrol.* **2018** Apr 19;19(1):92.
105. van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, **Ronco P**, Wetzels J. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. *Kidney Int.* **2018** Apr;93(4):1016-1017.
106. Li J, Cui Z, Long J, Huang W, Wang J, Zhang H, Wang H, Zhang L, **Ronco P**, Zhao MH. Primary glomerular nephropathy among hospitalized patients in a national database in China. *Nephrol Dial Transplant.* **2018** Dec 1;33(12):2173-2181.
107. Dinh A, Fessi H, Duran C, Batista R, Michelon H, Bouchand F, Lepeule R, Vittecoq D, Escaut L, Sobhani I, Lawrence C, Chast F, **Ronco P**, Davido B. Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study. *J Hosp Infect.* **2018** Aug;99(4):481-486.
108. Oba-Yabana I, Mori T, Takahashi C, Hirose T, Ohsaki Y, Kinugasa S, Muroya Y, Sato E, Nguyen G, Piedagnel R, **Ronco PM**, Totsune K, Ito S. Acidic organelles mediate TGF- $\beta$ 1-induced cellular fibrosis via (pro)renin receptor and vacuolar ATPase trafficking in human peritoneal mesothelial cells. *Sci Rep.* **2018** Feb 8;8(1):2648.
109. Ritz D, Sani E, Debiec H, **Ronco P**, Neri D, Fugmann T. Membran and Blood- Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition. *Proteomics.* **2018** Jun;18(12):e1700246.
110. Cez A, Brocheriou I, Lescure FX, Adam C, Girard PM, Pialoux G, Moestrup SK, Fellahi S, Bastard JP, **Ronco P**, Plaisier E. Decreased expression of megalin and cubilin and altered mitochondrial activity in tenofovir nephrotoxicity. *Hum Pathol.* **2018** Mar;73:89-101.
111. Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, Esnault VLM, Lambeau G, **Ronco P**. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. *J Am Soc Nephrol.* **2018** Feb;29(2):401-408.
112. Dorval G, Gribouval O, Martinez-Barquero V, Machuca E, Tête MJ, Baudouin V, Benoit S, Chabchoub I, Champion G, Chauveau D, Chehade H, Chouchane C, Cloarec S, Cochat P, Dahan K, Dantal J, Delmas Y, Deschênes G, Dolhem P, Durand D, Ekinci Z, El Karoui K, Fischbach M, Grunfeld JP, Guignon V, Hachicha M, Hogan J, Hourmant M, Hummel A, Kamar N, Krummel T, Lacombe D, Llanas B, Mesnard L, Mohsin N, Niaudet P, Nivet H, Parvex P, Pietrement C, de Pontual L, Noble CP, Ribes D, **Ronco P**, Rondeau E, Sallee M, Tsimaratos M, Ulinski T, Salomon R, Antignac C, Boyer O. Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome. *Pediatr Nephrol.* **2018** Mar;33(3):473-483.
113. Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, **Ronco P**, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O; French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON). Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. *Leuk Lymphoma.* **2018** Jun;59(6):1399-1405.
114. Vanham D, Hoekstra AY, Wada Y, Bouraoui F, de Roo A, Mekonnen MM, van de Bund WJ, Batelaan O, Pavelic P, Bastiaanssen WGM, Kumm M, Rockström J, Liu J, Bisselink B, **Ronco P**, Pistocchi A, Bidoglio G. Physical water scarcity metrics for monitoring progress towards SDG target 6.4: An evaluation of indicator 6.4.2 "Level of water stress". *Sci Total Environ.* **2018** Feb 1;613-614:218-232.

## 2017

115. Dahan K, Gillion V, Johanet C, Debiec H, **Ronco P**. The Role of PLA2R Antibody in Treatment of Membranous Nephropathy. *Kidney Int Rep.* **2017** Nov 3;3(2):498-501.
116. Berchtold L, Zanetta G, Dahan K, Mihout F, Peltier J, Guerrot D, Brochérou I, **Ronco P**, Debiec H. Efficacy and Safety of Rituximab in Hepatitis B Virus- Associated PLA2R-Positive Membranous Nephropathy. *Kidney Int Rep.* **2017** Sep 21;3(2):486-491.
117. Esteve E, Reguer S, Boissiere C, Chanéac C, Lugo G, Jouanneau C, Mocuta C, Thiaudière D, Leclercq N, Leyh B, Greisch JF, Berthault J, Daudon M, **Ronco P**, Bazin D. Flyscan opportunities in medicine: the case of quantum rattle based on gold quantum dots. *J Synchrotron Radiat.* **2017** Sep 1;24(Pt 5):991-999.
118. Philipponnet C, **Ronco P**, Aniot J, Kemény JL, Heng AE. Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. *Am J Kidney Dis.* **2017** Dec;70(6):874-877.
119. Wang J, Cui Z, Lu J, Probst C, Zhang YM, Wang X, Qu Z, Wang F, Meng LQ, Cheng XY, Liu G, Debiec H, **Ronco P**, Zhao MH. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. *Clin J Am Soc Nephrol.* **2017** Oct 6;12(10):1642-1651.
120. **Ronco P**, Debiec H. A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease. *Pflugers Arch.* **2017** Aug;469(7-8):997-1005.
121. Bastard JP, Fellahi S, Lescure FX, Capeau J, **Ronco P**, Plaisier E. Interest of the combined measurement of selected urinary proteins in the diagnosis approach in nephrology. *Ann Biol Clin (Paris).* **2017** Jun 1;75(3):327-333. English.
122. Rosenzweig M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, **Ronco P**. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. *Kidney Int.* **2017** Jul;92(1):227-237.

123. Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glasscock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, **Ronco P**, Rovin BH, Haas M. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. *Kidney Int.* **2017** Apr;91(4):787-789.
124. Pourcine F, Dahan K, Mihout F, Cachanado M, Brocheriou I, Debiec H, **Ronco P**. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. *PLoS One.* **2017** Mar 3;12(3):e0173201.
125. Gilquin B, Louwagie M, Jaquinod M, Cez A, Picard G, El Kholy L, Surin B, Garin J, Ferro M, Kofman T, Barau C, Plaisier E, **Ronco P**, Brun V. Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics. *Talanta.* **2017** Mar 1;164:77-84.
126. Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtsey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, **Ronco P**, Touchard G, Bridoux F. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. *Blood.* **2017** Mar 16;129(11):1437-1447.
127. Trouillet A, Lorach H, Dubus E, El Mathari B, Ivkovic I, Dégardin J, Simonutti M, Paques M, Guillonnet X, Sennlaub F, Sahel JA, **Ronco P**, Plaisier E, Picaud S. Col4a1 mutation generates vascular abnormalities correlated with neuronal damage in a mouse model of HANAC syndrome. *Neurobiol Dis.* **2017** Apr;100:52-61.
128. Guiraud S, Migeon T, Ferry A, Chen Z, Ouchelouche S, Verpont MC, Sado Y, Allamand V, **Ronco P**, Plaisier E. HANAC Col4a1 Mutation in Mice Leads to Skeletal Muscle Alterations due to a Primary Vascular Defect. *Am J Pathol.* **2017** Mar;187(3):505-516.
129. Jasiek M, Karras A, Le Guern V, Krastinova E, Mesbah R, Faguer S, Jourde- Chiche N, Fauchais AL, Chiche L, Dernis E, Moulis G, Fraison JB, Lazaro E, Jullien P, Hachulla E, Le Quellec A, Rémy P, Hummel A, Costedoat-Chalumeau N, **Ronco P**, Vanhille P, Meas-Yedid V, Cordonnier C, Ferlicot S, Daniel L, Seror R, Mariette X, Thervet E, François H, Terrier B. A multicentre study of 95 biopsy- proven cases of renal disease in primary Sjögren's syndrome. *Rheumatology (Oxford).* **2017** Mar 1;56(3):362-370.
130. Cui Z, Xie LJ, Chen FJ, Pei ZY, Zhang LJ, Qu Z, Huang J, Gu QH, Zhang YM, Wang X, Wang F, Meng LQ, Liu G, Zhou XJ, Zhu L, Lv JC, Liu F, Zhang H, Liao YH, Lai LH, **Ronco P**, Zhao MH. MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. *J Am Soc Nephrol.* **2017** May;28(5):1651-1664.
131. Kimura Y, Miura N, Debiec H, Morita H, Yamada H, Banno S, **Ronco P**, Imai H. Circulating antibodies to  $\alpha$ -enolase and phospholipase A<sub>2</sub> receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. *Clin Exp Nephrol.* **2017** Feb;21(1):117-126.
132. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, **Ronco P**; GEMRITUX Study Group. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. *J Am Soc Nephrol.* **2017** Jan;28(1):348-358.

## 2016

133. Caron J, Michel PA, Dussaule JC, Chatziantoniou C, **Ronco P**, Boffa JJ. Extracorporeal shock wave therapy does not improve hypertensive nephropathy. *Physiol Rep.* **2016** Jun;4(11):e12699.
134. Plaisier E, **Ronco P**. <i>COL4A1</i>-Related Disorders. **2009** Jun 25 [updated **2016** Jul 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. *GeneReviews* [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
135. Guerry MJ, Vanhille P, **Ronco P**, Debiec H. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. *Kidney Int.* **2016** Jun;89(6):1399.
136. Bally S, Debiec H, Ponard D, Dijoud F, Rendu J, Fauré J, **Ronco P**, Dumestre- Perard C. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan- Binding Lectin Deficiency. *J Am Soc Nephrol.* **2016** Dec;27(12):3539-3544.
137. Okpechi IG, Ameh OI, Bello AK, **Ronco P**, Swanepoel CR, Kengne AP. Epidemiology of Histologically Proven Glomerulonephritis in Africa: A Systematic Review and Meta-Analysis. *PLoS One.* **2016** Mar 24;11(3):e0152203.
138. Ardaillou R, **Ronco P**. Gabriel Richet: the Man and the Scientist. *G Ital Nefrol.* **2016** Feb;33 Suppl 66:33.S66.7.
139. Pencina MJ, Louzao DM, McCourt BJ, Adams MR, Tayyabkhan RH, **Ronco P**, Peterson ED. Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. *Am Heart J.* **2016** Feb;172:64-9.
140. Debiec H, **Ronco P**. Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy. *J Am Soc Nephrol.* **2016** May;27(5):1275-7.
141. Luciani A, Sirac C, Terryn S, Javaugue V, Prange JA, Bender S, Bonaud A, Cogné M, Aucouturier P, **Ronco P**, Bridoux F, Devuyst O. Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome. *J Am Soc Nephrol.* **2016** Jul;27(7):2049-61.
142. Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glasscock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, **Ronco P**, Fervenza FC. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. *J Am Soc Nephrol.* **2016** May;27(5):1278-87.
143. Zaidan M, Terrier B, Pozdzik A, Frouget T, Rioux-Leclercq N, Combe C, Lepreux S, Hummel A, Noël LH, Marie I, Legallier B, François A, Huart A, Launay D, Kaplanski G, Bridoux F, Vanhille P, Makdassi R, Augusto JF, Rouvier P, Karras A, Jouanneau C, Verpont MC, Callard P, Carrat F, Hermine O, Léger JM, Mariette X, Senet P, Saadoun D, **Ronco P**, Brocheriou I, Cacoub P, Plaisier E; CryoVas study group. Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. *J Am Soc Nephrol.* **2016** Apr;27(4):1213-24.
144. Chen Z, Migeon T, Verpont MC, Zaidan M, Sado Y, Kerjaschki D, **Ronco P**, Plaisier E. HANAC Syndrome Col4a1 Mutation Causes Neonate Glomerular Hyperpermeability and Adult Glomerulocystic Kidney Disease. *J Am Soc Nephrol.* **2016** Apr;27(4):1042-54.



## 2015

145. **Ronco P**, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. *Mol Immunol*. **2015** Nov;68(1):57-62.
146. Floege J, Mak RH, Molitoris BA, Remuzzi G, **Ronco P**. Nephrology research-- the past, present and future. *Nat Rev Nephrol*. **2015** Nov;11(11):677-87.
147. Pozdzik AA, Debiec H, I Brochériou, Husson C, Rorive S, Broeders N, Le Moine A, **Ronco P**, Nortier J. Anticorps anti-EPN et anti-PLA2R dans les glomerulopathies extramembraneuses: le point en 2014 [Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update]. *Rev Med Brux*. **2015** May- Jun;36(3):166-71. French.
148. Aline-Fardin A, Bender S, Fabiani B, Buob D, Brahimi S, Verpont MC, Mothy M, **Ronco P**, Boffa JJ, Aucouturier P, Garderet L. Pseudo-Peritoneal Carcinomatosis Presentation of a Crystal-Storing Histiocytosis With an Unmutated Monoclonal k Light Chain. *Medicine (Baltimore)*. **2015** Aug;94(32):e1247.
149. **Ronco P**, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. *Lancet*. **2015** May 16;385(9981):1983-92.
150. Bakey Z, Bihoreau MT, Piedagnel R, Delestré L, Arnould C, de Villiers Ad, Devuyt O, Hoffmann S, **Ronco P**, Gauguier D, Lelongt B. The SAM domain of ANKS6 has different interacting partners and mutations can induce different cystic phenotypes. *Kidney Int*. **2015** Aug;88(2):299-310.
151. **Ronco P**. Moderator's view: Biomarkers in glomerular diseases--translated into patient care or lost in translation? *Nephrol Dial Transplant*. **2015** Jun;30(6):899-902.
152. Mihout F, Joseph L, Brocheriou I, Leblond V, Varnous S, **Ronco P**, Plaisier E. Bilateral kidney infarction due to primary Al amyloidosis: a first case report. *Medicine (Baltimore)*. **2015** May;94(17):e777.
153. Stehlé T, Audard V, **Ronco P**, Debiec H. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. *Nephrol Dial Transplant*. **2015** Jun;30(6):1047-50.
154. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, **Ronco P**, Remuzzi G. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. *J Am Soc Nephrol*. **2015** Oct;26(10):2545-58.
155. Letavernier E, Vandermeersch S, Traxer O, Tligui M, Baud L, **Ronco P**, Haymann JP, Daudon M. Demographics and characterization of 10,282 Randall plaque-related kidney stones: a new epidemic? *Medicine (Baltimore)*. **2015** Mar;94(10):e566.
156. Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Bataille P, Bridoux F, Brignon P, Choquenot C, Cochat P, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N'Guyen HV, Noël C, Normand M, Pietak M, **Ronco P**, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M; French Cystinuria Group. CKD and Its Risk Factors among Patients with Cystinuria. *Clin J Am Soc Nephrol*. **2015** May 7;10(5):842-51.
157. Vivarelli M, Emma F, Pellé T, Gerken C, Pedicelli S, Diomedi-Camassei F, Klaus G, Waldegger S, **Ronco P**, Debiec H. Genetic homogeneity but IgG subclass- dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. *Kidney Int*. **2015** Mar;87(3):602-9.
158. Ardaillou RA, **Ronco PM**; Tenon community. Gabriel Richet (1916-2014). *Kidney Int*. **2015** Jan;87(1):3-4.

## 2014

159. Ardaillou R, **Ronco P**. Gabriel Richet (1916-2014). *Nephrol Dial Transplant*. **2014** Dec;29(12):2350-1.
160. **Ronco P**, Debiec H. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy. *Nephron Clin Pract*. **2014**;128(3-4):232-7.
161. Meyrier A, **Ronco P**. Allotransplantation using a diseased kidney: when a swallow makes a summer. *Nephrol Dial Transplant*. **2014** Dec;29(12):2164-6.
162. Smeets B, Stucker F, Wetzels J, Brocheriou I, **Ronco P**, Gröne HJ, D'Agati V, Fogo AB, van Kuppevelt TH, Fischer HP, Boor P, Floege J, Ostendorf T, Moeller MJ. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. *Am J Pathol*. **2014** Dec;184(12):3239-48.
163. Mihout F, Devuyt O, Bensman A, Brocheriou I, Ridet C, Wagner CA, Mohebbi N, Boffa JJ, Plaisier E, **Ronco P**. Acute metabolic acidosis in a GLUT2-deficient patient with Fanconi-Bickel syndrome: new pathophysiology insights. *Nephrol Dial Transplant*. **2014** Sep;29 Suppl 4:iv113-6.
164. Baruteau J, Heissat S, Broué P, Collardeau-Frachon S, Bouvier R, Fabre M, Debiec H, **Ronco P**, Uzan M, Narcy P, Cordier MP, Lachaux A, Lamireau T, Elleau C, Filet JP, Mitanchez D, Dupuy MP, Salaün JF, Odent S, Davison J, Debray D, Guignonis V. Transient neonatal liver disease after maternal antenatal intravenous Ig infusions in gestational alloimmune liver disease associated with neonatal haemochromatosis. *J Pediatr Gastroenterol Nutr*. **2014** Nov;59(5):629-35.
165. **Ronco P**, Floege J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? *Semin Immunopathol*. **2014** Jul;36(4):377-9.
166. Debiec H, **Ronco P**. Immunopathogenesis of membranous nephropathy: an update. *Semin Immunopathol*. **2014** Jul;36(4):381-97.
167. Sicard A, Karras A, Goujon JM, Sirac C, Bender S, Labatut D, Callard P, Sarkozy C, Essig M, Vanhille P, Provot F, Nony A, Nochy D, **Ronco P**, Bridoux F, Touchard G. Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. *Nephrol Dial Transplant*. **2014** Oct;29(10):1894-902.
168. Zaidan M, Stucker F, Stengel B, Vasiliu V, Hummel A, Landais P, Boffa JJ, **Ronco P**, Grünfeld JP, Servais A. Increased risk of solid renal tumors in lithium-treated patients. *Kidney Int*. **2014** Jul;86(1):184-90.
169. Chauvet S, Courbebaisse M, **Ronco P**, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. *Clin Nephrol*. **2014** Dec;82(6):402-6.
170. Debiec H, Valayannopoulos V, Boyer O, Noël LH, Callard P, Sarda H, de Lonlay P, Niaudet P, **Ronco P**. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. *J Am Soc Nephrol*. **2014** Apr;25(4):675-80.



## 2013

171. Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, Pommereau A, **Ronco P**, Kamar N, Merville P, Couzi L. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. *Transpl Infect Dis*. **2013** Dec;15(6):E211-5.
172. Coulibaly G, Kaboré GE, Diallo O, Ouédraogo DD, Fessi H, **Ronco P**, Zabsonré P, Lengani A. Prise en charge de l'insuffisance rénale terminale : un challenge pour les pays de l'Afrique subsaharienne Exemple des désordres minéralo-osseux au Burkina Faso [Management of end-stage kidney failure: a challenge for the countries of sub-Saharan Africa example of mineral and bone disorders in Burkina Faso]. *Med Sante Trop*. **2013** May 1;23(2):193-6. French.
173. Weening JJ, **Ronco P**, Remuzzi G. Advances in the pathology of glomerular diseases. *Contrib Nephrol*. **2013**;181:12-21.
174. **Ronco P**, Debiec H, Imai H. Circulating antipodocyte antibodies in membranous nephropathy: pathophysiologic and clinical relevance. *Am J Kidney Dis*. **2013** Jul;62(1):16-9.
175. Laville M, Godin M, Joly D, Houillier P, Brasseur J, Eladari D, Bataille P, Hannedouche T, **Ronco P**. Financement de la recherche en néphrologie : l'indispensable partenariat entre les sociétés scientifiques et la Fondation du rein [Funding research in nephrology: the essential partnership between scientific societies and Kidney Foundation]. *Nephrol Ther*. **2013** Apr;9(2):61-4. French.
176. Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland- Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, **Ronco P**. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. *J Am Soc Nephrol*. **2013** Mar;24(4):677-83.
177. Zaidan M, Lescure FX, Brochériou I, Dettwiler S, Guiard-Schmid JB, Pacanowski J, Rondeau E, Pialoux G, Girard PM, **Ronco P**, Plaisier E. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. *Clin J Am Soc Nephrol*. **2013** Jun;8(6):930-8.
178. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, **Ronco PM**, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. *Kidney Int*. **2013** Mar;83(3):511-6.
179. Duquesne A, Werbrouck A, Fabiani B, Denoyer A, Cervera P, Verpont MC, Bender S, Piedagnel R, Brocheriou I, **Ronco P**, Boffa JJ, Aucouturier P, Garderet L. Complete remission of monoclonal gammopathy with ocular and periorbital crystal storing histiocytosis and Fanconi syndrome. *Hum Pathol*. **2013** May;44(5):927-33.
180. Sendeyo K, Audard V, Zhang SY, Fan Q, Bouachi K, Ollero M, Rucker-Martin C, Gouadon E, Desvaux D, Bridoux F, Guellaën G, **Ronco P**, Lang P, Pawlak A, Sahali D. Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. *Kidney Int*. **2013** Mar;83(3):414-25.
181. **Ronco P**, Debiec H. Physiopathologie des glomérulopathies extramembraneuses - Cinquante ans de progrès, du laboratoire au patient [Pathophysiology of extramembranous glomerulopathies. Fifty years of progress, from laboratory to patient]. *Biol Aujourd'hui*. **2013**;207(4):249-59. French.
182. Svobodova B, Honsova E, **Ronco P**, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. *Nephrol Dial Transplant*. **2013** Jul;28(7):1839-44.
183. Surin B, Sachon E, Rougier JP, Steverlynck C, Garreau C, Lelongt B, **Ronco P**, Piedagnel R. LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy. *Proteomics*. **2013** Jan;13(1):142-52.

## 2012

184. **Ronco P**, Debiec H. Glomérulopathie extramembraneuse par immunisation materno-foetale [Anti-CD 10 maternal-fetal allo-immunisation]. *Bull Acad Natl Med*. **2012** Nov;196(8):1613-22; discussion 1622-3. French
185. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, Aucouturier P, Godin M, **Ronco P**. Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor. *J Am Soc Nephrol*. **2012** Dec;23(12):1949-54.
186. Bigé N, Lévy PP, Callard P, Faintuch JM, Chigot V, Jousset V, **Ronco P**, Boffa JJ. Renal arterial resistive index is associated with severe histological changes and poor renal outcome during chronic kidney disease. *BMC Nephrol*. **2012** Oct 25;13:139.
187. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, **Ronco P**, Brenchley PE, Wetzels JF. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. *J Am Soc Nephrol*. **2012** Oct;23(10):1735-43.
188. Cambier JF, **Ronco P**. Onco-nephrology: glomerular diseases with cancer. *Clin J Am Soc Nephrol*. **2012** Oct;7(10):1701-12.
189. Collardeau-Frachon S, Heissat S, Bouvier R, Fabre M, Baruteau J, Broue P, Cordier MP, Debray D, Debiec H, **Ronco P**, Guignonis V. French retrospective multicentric study of neonatal hemochromatosis: importance of autopsy and autoimmune maternal manifestations. *Pediatr Dev Pathol*. **2012** Nov- Dec;15(6):450-70.
190. Kerroch M, Guerrot D, Vandermeersch S, Placier S, Mesnard L, Jouanneau C, Rondeau E, **Ronco P**, Boffa JJ, Chatziantoniou C, Dussaule JC. Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis. *FASEB J*. **2012** Oct;26(10):4079-91.
191. Zaidan M, Ebbo M, Brochériou I, **Ronco P**, Schleinitz N, Boffa JJ. Les atteintes uro-néphrologiques au cours de la maladie associée aux IgG4 [IgG4-related disease and renal and urological involvement]. *Nephrol Ther*. **2012** Dec;8(7):499-507. French.
192. **Ronco P**, Debiec H. Pathophysiological lessons from rare associations of autoimmune diseases. *Clin Kidney J*. **2012** Apr;5(2):91-93.
193. Bollée G, Moulin B, Martinez F, Meulders Q, Rougier JP, Baumelou A, Glotz D, Subra JF, Ulinski T, Vrigneaud L, Brasseur J, Alhenc-Gelas M, Martin L, Daniel L, Kourilsky O, Deteix P, Sie P, **Ronco P**, Houillier P; Groupe de travail de la Société de Néphrologie. Pratique de la biopsie rénale: résultat d'une enquête en France, revue de la littérature et recommandations [Renal biopsy practice: results of a French study and recommendations]. *Nephrol Ther*. **2012** Jun;8(3):168-76. French.
194. Bige N, Shweke N, Benhassane S, Jouanneau C, Vandermeersch S, Dussaule JC, Chatziantoniou C, **Ronco P**, Boffa JJ. Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. *Kidney Int*. **2012** Jun;81(12):1226-38.
195. **Ronco P**, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. *Nat Rev Nephrol*. **2012** Feb 28;8(4):203-13.

196. Boffa JJ, Dussaule JC, **Ronco P**, Chatziantoniou C. Maladie rénale chronique, les voies de recherche thérapeutique [Chronic kidney disease, new therapeutic approaches]. *Rev Prat.* **2012** Jan;62(1):72-5. French.
197. Devuyst O, Antignac C, Bindels RJ, Chauveau D, Emma F, Gansevoort R, Maxwell PH, Ong AC, Remuzzi G, **Ronco P**, Schaefer F. The ERA-EDTA Working Group on inherited kidney disorders. *Nephrol Dial Transplant.* **2012** Jan;27(1):67-9.
198. Lescure FX, Flateau C, Pacanowski J, Brocheriou I, Rondeau E, Girard PM, **Ronco P**, Pialoux G, Plaisier E. HIV-associated kidney glomerular diseases: changes with time and HAART. *Nephrol Dial Transplant.* **2012** Jun;27(6):2349-55.
199. Plaisier E, Lescure FX, **Ronco P**. Rein et infection par le virus de l'immunodéficience humaine [Kidney and HIV infection]. *Presse Med.* **2012** Mar;41(3 Pt 1):267-75. French.
200. **Ronco P**. Maladies rénales: les nouveaux enjeux [Kidney diseases: new issues]. *Presse Med.* **2012** Mar;41(3 Pt 1):240-6. French.
201. **Ronco P**, Debiec H. Glomérulopathies extramembraneuses idiopathiques et secondaires [Idiopathic and secondary membranous nephropathies]. *Presse Med.* **2012** Mar;41(3 Pt 1):290-7. French.

## 2011

202. Boyer O, Nevo F, Plaisier E, Funalot B, Gribouval O, Benoit G, Huynh Cong E, Arrondel C, Tête MJ, Montjean R, Richard L, Karras A, Pouteil-Noble C, Balafrej L, Bonnardeaux A, Canaud G, Charasse C, Dantal J, Deschenes G, Deteix P, Dubourg O, Petiot P, Pouthier D, Leguern E, Guiochon-Mantel A, Broutin I, Gubler MC, Saunier S, **Ronco P**, Vallat JM, Alonso MA, Antignac C, Mollet G. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. *N Engl J Med.* **2011** Dec 22;365(25):2377-88.
203. Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, Mousson C, **Ronco P**. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. *Am J Transplant.* **2011** Oct;11(10):2144-52.
204. Debiec H, **Ronco P**. Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy. *Nat Rev Nephrol.* **2011** Aug 9;7(9):496-8.
205. Faguer S, Decramer S, Chassaing N, Bellanné-Chantelot C, Calvas P, Beauvils S, Bessenay L, Lengelé JP, Dahan K, **Ronco P**, Devuyst O, Chauveau D. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. *Kidney Int.* **2011** Oct;80(7):768-76.
206. Toly-Ndour C, Peltier J, Piedagnel R, Coppo P, Sachon E, **Ronco P**, Rondeau E, Callard P, Aucouturier P. Acute renal failure with lambda light chain-derived crystals in a patient with IgD myeloma. *Nephrol Dial Transplant.* **2011** Sep;26(9):3057-9.
207. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, Noel LH, Callard P, Delahousse M, **Ronco P**. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. *Clin J Am Soc Nephrol.* **2011** Jul;6(7):1609-16.
208. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, **Ronco P**. Early-childhood membranous nephropathy due to cationic bovine serum albumin. *N Engl J Med.* **2011** Jun 2;364(22):2101-10.
209. Boulous N, Helle F, Dussaule JC, Placier S, Milliez P, Djudjaj S, Guerrot D, Joutel A, **Ronco P**, Boffa JJ, Chatziantoniou C. Notch3 is essential for regulation of the renal vascular tone. *Hypertension.* **2011** Jun;57(6):1176-82.
210. Bridoux F, **Ronco P**, Gillmore J, Femand JP. Renal transplantation in light chain amyloidosis: coming out of the cupboard. *Nephrol Dial Transplant.* **2011** Jun;26(6):1766-8.
211. Zaidan M, Cervera-Pierot P, de Seigneux S, Dahan K, Fabiani B, Callard P, **Ronco P**, Aucouturier P. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. *Nephrol Dial Transplant.* **2011** Jun;26(6):2047-50.
212. **Ronco P**, Debiec H. Advances in membranous nephropathy: success stories of a long journey. *Clin Exp Pharmacol Physiol.* **2011** Jul;38(7):460-6.
213. Debiec H, **Ronco P**. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. *N Engl J Med.* **2011** Feb 17;364(7):689-90.
214. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundry V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeny LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, **Ronco P**, Mathieson PW, Kleita R. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. *N Engl J Med.* **2011** Feb 17;364(7):616-26.
215. Hertig A, Bonnard G, Ulinski T, Colombat M, Jouanneau C, Baugey E, Bensman A, **Ronco P**, Rondeau E, Xu-Dubois YC. Tubular nuclear accumulation of Snail and epithelial phenotypic changes in human myeloma cast nephropathy. *Hum Pathol.* **2011** Aug;42(8):1142-8.
216. **Ronco P**, Plaisier E, Aucouturier P. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. *Contrib Nephrol.* **2011**;169:221-231.
217. Michel PA, Dahan K, Ancel PY, Plaisier E, Mojaat R, De Seigneux S, Daugas E, Matignon M, Mesnard L, Karras A, François H, Pardon A, Caudwell V, Debiec H, **Ronco P**. Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. *Nephron Extra.* **2011** Jan;1(1):251-61.
218. Knehtl M, Debiec H, Kamgang P, Callard P, Cadranel J, **Ronco P**, Boffa JJ. A case of phospholipase A<sub>2</sub> receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. *Am J Kidney Dis.* **2011** Jan;57(1):140-3.
219. Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, **Ronco P**, Chatziantoniou C, Boffa JJ. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF- $\beta$ 1 synthesis. *J Pathol.* **2011** Jan;223(1):37-45.

## 2010

220. Dahan K, Albert C, Arlet JB, Callard P, **Ronco P**. Non-Randall proliferative glomerulonephritis with humps and monotypic IgG deposits in primary Sjögren's syndrome: a first case report. *NDT Plus.* **2010** Dec;3(6):558-63.
221. **Ronco P**, Plaisier E, Aucouturier P. Ig-related renal disease in lymphoplasmacytic disorders: an update. *Semin Nephrol.* **2010** Nov;30(6):557-69.

222. Plaisier E, Chen Z, Gekeler F, Benhassine S, Dahan K, Marro B, Alamowitch S, Paques M, **Ronco P**. Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain. *Am J Med Genet A*. **2010** Oct;152A(10):2550-5.
223. Zhang SY, Kamal M, Dahan K, Pawlak A, Ory V, Desvaux D, Audard V, Candelier M, BenMohamed F, Matignon M, Christov C, Decroux X, Bernard V, Mangiapan G, Lang P, Guellaën G, **Ronco P**, Sahali D. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. *Sci Signal*. **2010** May 18;3(122):ra39.
224. de Seigneux S, Bindi P, Debiec H, Alyanakian MA, Aymard B, Callard P, **Ronco P**, Aucouturier P. Immunoglobulin deposition disease with a membranous pattern and a circulating monoclonal immunoglobulin G with charge-dependent aggregation properties. *Am J Kidney Dis*. **2010** Jul;56(1):117-21.
225. Bollée G, Martinez F, Moulin B, Meulders Q, Rougier JP, Baumelou A, Glotz D, Subra JF, Ulinski T, Vrigneaud L, Brasseur J, Martin L, Daniel L, Kourilsky O, Deteix P, Sie P, **Ronco P**, Houillier P. Renal biopsy practice in France: results of a nationwide study. *Nephrol Dial Transplant*. **2010** Nov;25(11):3579-85.
226. Grünfeld JP, Hwu W, Chien Y, Lee N, Chiang S, Dobrovolsky R, Huang A, Yeh H, Chao M, Lin S, Kitagawa T, Desnick R, Hsu L, Van Keimpema L, Nevens F, Vanslembrouck R, Van Oijen G, Hoffmann A, Dekker H, De Man R, Drenth J, Alamovitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agrmael T, Marro B, **Ronco P**, Zivna M, Hulkova H, Matignon M, Hodanova K, Vylet'al P, Kalbacova M, Baresova V, Sikora J, Blazkova H, Zivny J, Ivanek R, Stranecky V, Sovova J, Claes K, Lerut E, Fryns J, Hart P, Hart T, Adams J, Pawtowski A, Clemessy M, Gasc J, Gubler M, Antignac C, Elleder M, Kapp K, Grimbert P, Bleyer A, Kmoch S, Brown E, Schlöndorff J, Becker Dj, Tsukaguchi H, Uschinski A, Higgs H, Henderson J, Pollak M. More on clinical renal genetics. *Clin J Am Soc Nephrol*. **2010** Apr;5(4):563-7.
227. **Ronco P**, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. *J Am Soc Nephrol*. **2010** Apr;21(4):564-9.
228. Coppo R, Dahan MR, Egido J, El-Nahas M, Feehally J, Floege J, Gesualdo L, Holthofer H, Remuzzi G, **Ronco P**; ERA-EDTA Immunonephrology Working Group. ERA- EDTA Immunonephrology working group. *Nephrol Dial Transplant*. **2010** May;25(5):1706-7.
229. **Ronco P**. Disease classification: a pitfall of the ERA/EDTA registry? *Nephrol Dial Transplant*. **2010** Apr;25(4):1022-4.
230. **Ronco P**, Debiec H. First identification of an antigen in autoimmune idiopathic membranous nephropathy: toward targeted therapy? *Am J Kidney Dis*. **2010** May;55(5):820-3.
231. **Ronco P**, Debiec H. Membranous glomerulopathy: the evolving story. *Curr Opin Nephrol Hypertens*. **2010** May;19(3):254-9.
232. Favre G, Courtellemont C, Callard P, Colombat M, Cabane J, Boffa JJ, Aucouturier P, **Ronco P**. Membranoproliferative glomerulonephritis, chronic lymphocytic leukemia, and cryoglobulinemia. *Am J Kidney Dis*. **2010** Feb;55(2):391-4.
233. Maigne G, Ferlicot S, Galacteros F, Belenfant X, Ulinski T, Niaudet P, **Ronco P**, Godeau B, Durbach A, Sahali S, Lang P, Lambotte O, Audard V. Glomerular lesions in patients with sickle cell disease. *Medicine (Baltimore)*. **2010** Jan;89(1):18-27.

## 2009

234. Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agrmael T, Marro B, **Ronco P**. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. *Neurology*. **2009** Dec 1;73(22):1873-82.
235. Noel N, Meignin V, Rosenstingl S, **Ronco P**, Boffa JJ. Nephrotic syndrome associated with immune thrombocytopenia revealing Kimura's disease in a non- Asian male. *NDT Plus*. **2009** Dec;2(6):452-4.
236. Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougnot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, **Ronco P**, Plaisier E, Grimbert P. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. *Medicine (Baltimore)*. **2009** Nov;88(6):341-348.
237. Boffa JJ, Rougier JP, Noël N, **Ronco P**. Le risque cardiovasculaire accru du lupus: données physiopathologiques et thérapeutiques [High cardiovascular complications in systemic lupus erythematosus: physiopathology and risk management]. *Nephrol Ther*. **2009** Dec;5(7):595-602. French.
238. Arnould C, Lelièvre-Pégorier M, **Ronco P**, Lelongt B. MMP9 limits apoptosis and stimulates branching morphogenesis during kidney development. *J Am Soc Nephrol*. **2009** Oct;20(10):2171-80.
239. Hills CE, Bland R, Bennett J, **Ronco PM**, Squires PE. TGF-beta1 mediates glucose-evoked up-regulation of connexin-43 cell-to-cell communication in HCD- cells. *Cell Physiol Biochem*. **2009**;24(3-4):177-86.
240. **Ronco P**, Aucouturier P. Renal involvement in AL amyloidosis: the facts, the promise and the hope. *Nephrol Dial Transplant*. **2009** Oct;24(10):2967-9.
241. Bengatta S, Arnould C, Letavernier E, Monge M, de Préneuf HM, Werb Z, **Ronco P**, Lelongt B. MMP9 and SCF protect from apoptosis in acute kidney injury. *J Am Soc Nephrol*. **2009** Apr;20(4):787-97.
242. Devuyst O, Meij I, Jeunemaitre X, **Ronco P**, Antignac C, Christensen EI, Knoers NV, Levtschenko EN, Deen PM, Müller D, Wagner CA, Rampoldi L, van't Hoff WG; EUNEFron consortium. EUNEFron, the European Network for the Study of Orphan Nephropathies. *Nephrol Dial Transplant*. **2009** Jul;24(7):2011-5.
243. **Ronco P**, Debiec H, Guigonis V. Allo-immunisation foeto-maternelle anti-CD10 [Anti-CD10 fetomaternal alloimmunisation]. *Med Sci (Paris)*. **2009** Jan;25(1):64-8. French.
244. **Ronco P**, Debiec H. Pathophysiological lessons from rare associations of immunological disorders. *Pediatr Nephrol*. **2009** Jan;24(1):3-8.

## 2008

245. Plaisier E, **Ronco P**. Syndrome HANAC (hereditary angiopathy with nephropathy, aneurysms and muscle cramps) et mutations du gène COL4A1: une nouvelle basalopathie héréditaire à expression multisystémique [HANAC syndrome (hereditary angiopathy with nephropathy, aneurysms and muscle cramps) and mutations of the collagen 4A1 gene: a new basement membrane hereditary pathology with multisystemic expression]. *Nephrol Ther*. **2008** Dec;4(7):632-4. French.
246. **Ronco P**. Glomérulonéphrites extramembraneuses: du modèle expérimental à la pathologie humaine du nouveau-né et de l'adulte [Extra-membranous glomerulonephritis: from the experimental model to the human pathology of new-born and adult]. *Bull Mem Acad R Med Belg*. **2008**;163(3-4):179-86; discussion 186-8. French.

247. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, **Ronco P**, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G. Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. *Nephrol Dial Transplant*. **2008** Dec;23(12):3731-7.
248. Shweke N, Boulous N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, **Ronco P**, Boffa JJ. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. *Am J Pathol*. **2008** Sep;173(3):631-42.
249. **Ronco P**, Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. *Kidney Int*. **2008** Oct;74(7):873-8.
250. Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, **Ronco P**. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. *Clin J Am Soc Nephrol*. **2008** Sep;3(5):1339-49.
251. Guerrot D, François A, Boffa JJ, Boulous N, Hanoy M, Legallicier B, Triquenot-Bagan A, Guyant-Marechal L, Laquerriere A, Freguin-Bouilland C, **Ronco P**, Godin M. Nephroangiosclerosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: is NOTCH3 mutation the common culprit? *Am J Kidney Dis*. **2008** Aug;52(2):340-5.
252. Yamamoto T, Langham RG, **Ronco P**, Knepper MA, Thongboonkerd V. Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA. *Proteomics*. **2008** Jun;8(11):2156-9.
253. Guignon V, Dallochio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, **Ronco P**, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. *Pediatr Nephrol*. **2008** Aug;23(8):1269-79.
254. **Ronco P**, Plaisier E. Angiopathie héréditaire avec néphropathie, anévrismes et crampes musculaires (AHNAC): une nouvelle maladie des membranes basales associée à des mutations du gène COL4A1 (gène codant pour la chaîne alpha1 du collagène de type IV) [Hereditary angiopathy with nephropathy, aneurysms and muscle cramps (HANAC): a new basement membrane-disease associated with mutations of the COL4A1 gene]. *Bull Acad Natl Med*. **2008** May;192(5):971-84; discussion 984-6. French.
255. François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, **Ronco P**. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. *Am J Kidney Dis*. **2008** Feb;51(2):298-301.
256. Bockenhauer D, Debiec H, Sebire N, Barratt M, Warwicker P, **Ronco P**, Kleta R. Familial membranous nephropathy: an X-linked genetic susceptibility? *Nephron Clin Pract*. **2008**;108(1):c10-5.
257. Allory Y, Audard V, Fontanges P, **Ronco P**, Debiec H. The L1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis. *Kidney Int*. **2008** Mar;73(6):751-8.

## 2007

258. Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C, Verpont MC, Marro B, Desmettre T, Cohen SY, Rouillet E, Dracon M, Fardeau M, Van Agtmael T, Kerjaschki D, Antignac C, **Ronco P**. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. *N Engl J Med*. **2007** Dec 27;357(26):2687-95.
259. Bienaimé F, Clerbaux G, Plaisier E, Mougenot B, **Ronco P**, Rougier JP. D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. *Am J Kidney Dis*. **2007** Nov;50(5):821-5.
260. Arnaud L, Huart A, Plaisier E, Francois H, Mougenot B, Tiev K, Kettaneh A, **Ronco P**, Rougier JP. ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the "normotensive scleroderma renal crisis". *Clin Nephrol*. **2007** Sep;68(3):165-70.
261. Debiec H, **Ronco P**. Fetomaternal alloimmunization with antenatal glomerulopathies. *Ann N Y Acad Sci*. **2007** Sep;1110:559-66.
262. **Ronco P**, Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. *Semin Immunopathol*. **2007** Nov;29(4):445-58.
263. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, **Ronco P**, Quet F, Cogne M, Femand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *N Engl J Med*. **2007** Sep 13;357(11):1083-93.
264. Sellier-Leclerc AL, Duval A, Riveron S, Macher MA, Deschenes G, Loirat C, Verpont MC, Peuchmaur M, **Ronco P**, Monteiro RC, Haddad E. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. *J Am Soc Nephrol*. **2007** Oct;18(10):2732-9.
265. **Ronco P**, Debiec H. Podocyte antigens and glomerular disease. *Nephron Exp Nephrol*. **2007**;107(2):e41-6.
266. **Ronco P**. Proteinuria: is it all in the foot? *J Clin Invest*. **2007** Aug;117(8):2079-82.
267. Stengel B, Antignac C, Baverel G, Choukroun G, Cussenot O, Dussaule JC, Friedlander G, Lang P, Lelièvre-Pégorier M, Massy Z, Monteiro R, Parini A, Souillou JP, Baud L, **Ronco P**. Programme national de recherche sur les maladies du rein et des voies urinaires [Renal and urinary tract disease national research program]. *Nephrol Ther*. **2007** Jul;3(4):157-62. French.
268. Boffa JJ, **Ronco P**. Stratégies pour faire régresser les lésions de fibrose rénale [Strategies to reverse fibrotic lesions of the kidney]. *Presse Med*. **2007** Dec;36(12 Pt 2):1857-64. French
269. **Ronco P**, Lelongt B, Piedagnel R, Chatziantoniou C. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. *Semin Nephrol*. **2007** May;27(3):352-62.
270. Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, **Ronco P**, Rondeau E, Fain O. Renal granulomatosis: a retrospective study of 40 cases and review of the literature. *Medicine (Baltimore)*. **2007** May;86(3):170-180.
271. François H, Daugas E, Bensman A, **Ronco P**. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. *Am J Kidney Dis*. **2007** Jan;49(1):158-61.

## 2006

272. Hills CE, Bland R, Bennett J, **Ronco PM**, Squires PE. High glucose up-regulates ENaC and SGK1 expression in HCD-cells. *Cell Physiol Biochem*. **2006**;18(6):337-46.

273. **Ronco P**, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology- driven therapy. *Clin J Am Soc Nephrol*. **2006** Nov;1(6):1342-50.
274. Daugas E, Plaisier E, Boffa JJ, Guiard-Schmid JB, Pacanowski J, Mougenot B, **Ronco P**. Acute renal failure associated with immune restoration inflammatory syndrome. *Nat Clin Pract Nephrol*. **2006** Oct;2(10):594-8; quiz 599.
275. **Ronco P**, Debiec H, Guignonis V. Mechanisms of disease: Alloimmunization in renal diseases. *Nat Clin Pract Nephrol*. **2006** Jul;2(7):388-97.
276. Nortier JL, Debiec H, Tournay Y, Mougenot B, Noël JC, Deschodt-Lanckman MM, Janssen F, **Ronco P**. Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring. *Pediatr Nephrol*. **2006** Oct;21(10):1399-405.
277. Boulanger E, Fuentes V, Meignin V, Mougenot B, Labaume S, Gouilleux-Gruart V, Cogné M, Aucouturier P, Clauvel JP, **Ronco P**, Lassoued K. Polyclonal IgG4 hypergammaglobulinemia associated with plasmacytic lymphadenopathy, anemia and nephropathy. *Ann Hematol*. **2006** Dec;85(12):833-40.
278. Rivet J, Lebbé C, Urena P, Cordoliani F, Martinez F, Baglin AC, Aubert P, Aractingi S, **Ronco P**, Fournier P, Janin A. Cutaneous calcification in patients with end-stage renal disease: a regulated process associated with in situ osteopontin expression. *Arch Dermatol*. **2006** Jul;142(7):900-6.
279. Theilig F, Debiec H, Nafz B, **Ronco P**, Nüsing R, Seyberth HW, Pavenstädt H, Bouby N, Bachmann S. Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat). *Am J Physiol Renal Physiol*. **2006** Nov;291(5):F987-94.
280. **Ronco P**, Debiec H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. *J Am Soc Nephrol*. **2006** Jul;17(7):1772-4.
281. Boufi M, Ghaffari P, Allaire E, Fessi H, **Ronco P**, Vayssairat M. Foot gangrene in patients with end-stage renal disease: a case control study. *Angiology*. **2006** May-Jun;57(3):355-61.
282. Hills CE, Bland R, Wheelans DC, Bennett J, **Ronco PM**, Squires PE. Glucose- evoked alterations in connexin43-mediated cell-to-cell communication in human collecting duct: a possible role in diabetic nephropathy. *Am J Physiol Renal Physiol*. **2006** Nov;291(5):F1045-51.
283. Audard V, Larousserie F, Grimbret P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, **Ronco P**, Sahali D, Lang P, Hermine O. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. *Kidney Int*. **2006** Jun;69(12):2251-60.
284. **Ronco P**, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. *Curr Opin Nephrol Hypertens*. **2006** May;15(3):258-63.
285. Allory Y, Commo F, Boccon-Gibod L, Sibony M, Callard P, **Ronco P**, Debiec H. Sulfated HNK-1 epitope in developing and mature kidney: a new marker for thin ascending loop of Henle and tubular injury in acute tubular necrosis. *J Histochem Cytochem*. **2006** May;54(5):575-84.
286. Guignonis V, Debiec H, Deschênes G, Bensman A, **Ronco P**. Allo-immunisation maternofoetale tissulaire: nouvelles cibles antigéniques, nouvelles idées [Tissular maternofetal immunization: new antigenic targets, new ideas]. *Arch Pediatr*. **2006** Jan;13(1):4-5. French.
287. Grimaldi D, Daugas E, Mougenot B, Rossert J, **Ronco P**. Immuno-allergic interstitial nephritis related to fluindione: first biopsy proven cases. *Nephrol Dial Transplant*. **2006** Jan;21(1):237.
288. Piedagnel R, Tiger Y, Lelongt B, **Ronco PM**. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. *J Cell Physiol*. **2006** Feb;206(2):394-401.

## 2005

289. Plaisier E, Mougenot B, Verpont MC, Jouanneau C, Archelos JJ, Martini R, Kerjaschki D, **Ronco P**. Glomerular permeability is altered by loss of P0, a myelin protein expressed in glomerular epithelial cells. *J Am Soc Nephrol*. **2005** Nov;16(11):3350-6.
290. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, **Ronco P**, Santhorawala V, Sezer O, Solomon A, Gâteaux G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *Am J Hematol*. **2005** Aug;79(4):319-28.
291. Plaisier E, Alamowitch S, Gribouval O, Mougenot B, Gaudric A, Antignac C, Roulet E, **Ronco P**. Autosomal-dominant familial hematuria with retinal arteriolar tortuosity and contractures: a novel syndrome. *Kidney Int*. **2005** Jun;67(6):2354-60.
292. **Ronco P**, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. *J Am Soc Nephrol*. **2005** May;16(5):1205-13.
293. Boulanger E, Moranne O, Wautier MP, Rougier JP, **Ronco P**, Pagniez D, Wautier JL. La biocompatibilité des solutions de dialyse péritonéale [Biocompatibility of peritoneal dialysis fluids]. *Nephrol Ther*. **2005** Mar;1(1):14-22. French.
294. Plaisier E, Ribes D, **Ronco P**, Rossert J. Identification of two candidate collecting duct cell-specific cis-acting elements in the Hoxb-7 promoter region. *Biochim Biophys Acta*. **2005** Feb 14;1727(2):106-15.
295. Allory Y, Matsuoka Y, Bazille C, Christensen EI, **Ronco P**, Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. *Clin Cancer Res*. **2005** Feb 1;11(3):1190-7.
296. Meier P, Dayer E, **Ronco P**, Blanc E. Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end- stage renal failure. *Clin Nephrol*. **2005** Jan;63(1):8-21.

## 2004

297. Debiec H, Nauta J, Coulet F, van der Burg M, Guignonis V, Schurmans T, de Heer E, Soubrier F, Janssen F, **Ronco P**. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. *Lancet*. **2004** Oct 2-8;364(9441):1252-9.
298. Chatziantoniou C, Boffa JJ, Tharaux PL, Flamant M, **Ronco P**, Dussaule JC. Progression and regression in renal vascular and glomerular fibrosis. *Int J Exp Pathol*. **2004** Feb;85(1):1-11.
299. Alric L, Plaisier E, Thébaud S, Péron JM, Rostaing L, Pourrat J, **Ronco P**, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus- associated cryoglobulinemic MPGN. *Am J Kidney Dis*. **2004** Apr;43(4):617-23.

300. **Ronco P.** Predicting the outcome of human renal diseases by gene expression profiling: myth or reality? *Kidney Int.* **2004** Mar;65(3):1107-8.
301. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, **Ronco P**, Brouet JC, Femand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. *Kidney Int.* **2004** Feb;65(2):642-8.

## 2003

302. Farres MT, **Ronco P**, Saadoun D, Remy P, Vincent F, Khalil A, Le Blanche AF. Chronic lithium nephropathy: MR imaging for diagnosis. *Radiology.* **2003** Nov;229(2):570-4.
303. Rougier JP, **Ronco P.** Mécanismes des glomérulonéphrites immunes [Pathogenesis of immune glomerulonephritis]. *Rev Prat.* **2003** Nov 30;53(18):1998-2004. French.
304. Debiec H, Guignon V, Mougenot B, Haymann JP, Bensman A, Deschênes G, **Ronco P.** Les glomérulonéphrites extra-membraneuses: histoire d'une famille et nouveaux concepts physiopathologiques [Extra-membranous glomerulonephritis: report of a family and new physiopathological concepts]. *Bull Acad Natl Med.* **2003**;187(5):921-32; discussion 932-4. French.
305. Hong G, Lockhart A, Davis B, Rahmouni H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, **Ronco P**, Brown J. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. *FASEB J.* **2003** Oct;17(13):1966-8.
306. Meier P, Farres MT, Mougenot B, Jacob L, Le Goas F, Antignac C, **Ronco P.** Imaging medullary cystic kidney disease with magnetic resonance. *Am J Kidney Dis.* **2003** Jul;42(1):E5-10.
307. Lelongt B, **Ronco P.** Role of extracellular matrix in kidney development and repair. *Pediatr Nephrol.* **2003** Aug;18(8):731-42.
308. Debiec H, Guignon V, Mougenot B, Haymann JP, Bensman A, Deschênes G, **Ronco PM.** Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. *J Am Soc Nephrol.* **2003** Jun;14 Suppl 1:S27-32.
309. Legoupil N, **Ronco P**, Berenbaum F. Arthritis-related shunt nephritis in an adult. *Rheumatology (Oxford).* **2003** May;42(5):698-9.

## 2002

310. **Ronco P.** Le concept de néphroprotection: vers des thérapeutiques préventives et curatives de la sclérose rénale [The concept of nephroprotection: toward preventive and curative therapies for renal sclerosis]. *J Soc Biol.* **2002**;196(4):285-91. French.
311. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, **Ronco P**, Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. *Am J Kidney Dis.* **2002** Dec;40(6):1331-3.
312. Debiec H, Kutsche M, Schachner M, **Ronco P.** Abnormal renal phenotype in L1 knockout mice: a novel cause of CAKUT. *Nephrol Dial Transplant.* **2002**;17 Suppl 9:42-4.
313. Lelongt B, **Ronco P.** Role of matrix metalloproteinases in kidney development and glomerulopathy: lessons from transgenic mice. *Nephrol Dial Transplant.* **2002**;17 Suppl 9:28-31.
314. Plaisier E, Borradori L, Hellmark T, Wattiaux MJ, Flageul B, Mougenot B, **Ronco P.** Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-alpha 3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn's disease. *Am J Kidney Dis.* **2002** Sep;40(3):649-54.
315. Lerolle N, Lantz B, Paillard F, Gattegno B, Flahault A, **Ronco P**, Houillier P, Rondeau E. Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria. *Am J Med.* **2002** Aug 1;113(2):99-103.
316. Cittanova ML, Estepa L, Bourbouze R, Blanc O, Verpont MC, Wahbe E, Coriat P, Daudon M, **Ronco PM.** Fluoride ion toxicity in rabbit kidney thick ascending limb cells. *Eur J Anaesthesiol.* **2002** May;19(5):341-9.
317. Debiec H, Guignon V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, **Ronco PM.** Antenatal membranous glomerulonephritis due to anti- neutral endopeptidase antibodies. *N Engl J Med.* **2002** Jun 27;346(26):2053-60.
318. Terraz C, Brideau G, **Ronco P**, Rossert J. A combination of cis-acting elements is required to activate the pro-alpha 1(I) collagen promoter in tendon fibroblasts of transgenic mice. *J Biol Chem.* **2002** May 24;277(21):19019-26.
319. Meier P, Dautheville-Guibal S, **Ronco PM**, Rossert J. Cidofovir-induced end- stage renal failure. *Nephrol Dial Transplant.* **2002** Jan;17(1):148-9.

## 2001

320. Lerolle N, Coulet F, Lantz B, Paillard F, Houillier P, Soubrier F, Gattegno B, Jeunemaitre X, **Ronco P**, Rondeau E. No evidence for point mutations of the calcium-sensing receptor in familial idiopathic hypercalciuria. *Nephrol Dial Transplant.* **2001** Dec;16(12):2317-22.
321. Stahl D, Venetz JP, Lacroix-Desmazes S, Rondeau E, Bonnin E, Kazatchkine MD, **Ronco P**, Kaveri SV. Idiopathic membranous glomerulonephritis is associated with altered patterns of self-reactive IgM and IgG antibody repertoires. *Scand J Immunol.* **2001** Nov;54(5):534-42.
322. Legallier B, Trugnan G, Murphy G, Lelongt B, **Ronco P.** Expression of the type IV collagenase system during mouse kidney development and tubule segmentation. *J Am Soc Nephrol.* **2001** Nov;12(11):2358-2369.
323. Bland R, Zehnder D, Hughes SV, **Ronco PM**, Stewart PM, Hewison M. Regulation of vitamin D-1alpha-hydroxylase in a human cortical collecting duct cell line. *Kidney Int.* **2001** Oct;60(4):1277-86.
324. Terraz C, Toman D, Delauche M, **Ronco P**, Rossert J. delta Ef1 binds to a far upstream sequence of the mouse pro-alpha 1(I) collagen gene and represses its expression in osteoblasts. *J Biol Chem.* **2001** Oct 5;276(40):37011-9.
325. **Ronco PM**, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. *J Am Soc Nephrol.* **2001** Jul;12(7):1558-1565.
326. Locatelli F, Berthouix F, **Ronco P**, Valderrabano F, Andrulli S. Patterns of the abstracts submitted and accepted at the Congresses of ERA-EDTA Madrid (1999) and ERA-EDTA and EKRA Nice (2000). *Nephrol Dial Transplant.* **2001** Jun;16(6):1117-9.

327. Rossert J, **Ronco P**. Comment ralentir l'évolution de l'insuffisance rénale chronique [How to slow the progression of chronic renal insufficiency]. *Rev Prat*. **2001** Feb 28;51(4):378-84. French.
328. Lelongt B, Bengatta S, Delauche M, Lund LR, Werb Z, **Ronco PM**. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. *J Exp Med*. **2001** Apr 2;193(7):793-802.
329. Fischer EA, Verpont MC, Garrett-Sinha LA, **Ronco PM**, Rossert JA. Klf6 is a zinc finger protein expressed in a cell-specific manner during kidney development. *J Am Soc Nephrol*. **2001** Apr;12(4):726-735.
330. Lelongt B, Legallicier B, Piedagnel R, **Ronco PM**. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? *Curr Opin Nephrol Hypertens*. **2001** Jan;10(1):7-12.

## 2000

331. **Ronco P**, Aucouturier P, Mougnot B. Plasma cell dyscrasia-related glomerulopathies and Fanconi's syndrome: a molecular approach. *J Nephrol*. **2000** Nov-Dec;13 Suppl 3:S34-44.
332. Fischer E, Mougnot B, Callard P, **Ronco P**, Rossert J. Abnormal expression of glomerular basement membrane laminins in membranous glomerulonephritis. *Nephrol Dial Transplant*. **2000** Dec;15(12):1956-64.
333. Calmont A, Reichwald K, **Ronco P**, Rossert J. Identification of a short cis- acting element in the human vasopressin type 2 receptor gene which confers high- level expression of a reporter gene specifically in collecting duct cells. *Mol Endocrinol*. **2000** Oct;14(10):1682-95.
334. Lauque D, Cadranet J, Lazor R, Pourrat J, **Ronco P**, Guillemin L, Cordier JF. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). *Medicine (Baltimore)*. **2000** Jul;79(4):222-33.
335. Messiaen T, Deret S, Mougnot B, Bridoux F, Dequiedt P, Dion JJ, Makdassi R, Meeus F, Pourrat J, Touchard G, Vanhille P, Zaoui P, Aucouturier P, **Ronco PM**. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. *Medicine (Baltimore)*. **2000** May;79(3):135-54.
336. **Ronco P**, Rossert J. Pour freiner la progression. Les faits, les promesses et les questions [Inhibiting disease progression. Facts, promises and questions]. *Presse Med*. **2000** Apr 15;29(14):797-9. French
337. Farres MT, Gattegno B, **Ronco P**, Flahault A, Paula-Souza R, Bigot JM. Nonnephrotoxic, dynamic, contrast enhanced magnetic resonance urography: use in nephrology and urology. *J Urol*. **2000** Apr;163(4):1191-6; quiz 1295.

## 1999

338. Tattevin P, Fischer EA, **Ronco PM**, Rossert JA, Vasseur E, Mougnot B. Granulomatous nephritis in an AIDS patient treated with combination antiretroviral therapy and infection with Mycobacterium avium. *Am J Med*. **1999** Dec;107(6):642-3.
339. Volland H, Pradelles P, **Ronco P**, Azizi M, Simon D, Créminon C, Grassi J. A solid-phase immobilized epitope immunoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma. *J Immunol Methods*. **1999** Aug 31;228(1-2):37-47.
340. Denamur E, Bocquet N, Mougnot B, Da Silva F, Martinat L, Loirat C, Elion J, Bensman A, **Ronco PM**. Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases. *J Am Soc Nephrol*. **1999** Oct;10(10):2219-23.
341. **Ronco PM**. Paraneoplastic glomerulopathies: new insights into an old entity. *Kidney Int*. **1999** Jul;56(1):355-77.
342. **Ronco P**. Facteurs de progression de l'insuffisance rénale chronique et leur prévention [Factors of progression and chronic renal insufficiency and their prevention]. *Bull Acad Natl Med*. **1999**;183(1):65-77. French.
343. Déret S, Denoroy L, Lamarine M, Vidal R, Mougnot B, Frangione B, Stevens FJ, **Ronco PM**, Aucouturier P. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. *Protein Eng*. **1999** Apr;12(4):363-9.
344. Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, **Ronco PM**, Mougnot B. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. *J Am Soc Nephrol*. **1999** Mar;10(3):519-28.
345. **Ronco PM**, Aucouturier P. The molecular bases of plasma cell dyscrasia- related renal diseases. *Nephrol Dial Transplant*. **1999**;14 Suppl 1:4-8.
346. Piedagnel R, Murphy G, **Ronco PM**, Lelongt B. Matrix metalloproteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. *J Biol Chem*. **1999** Jan 15;274(3):1614-20.

## 1998

347. Debiec H, Christensen EI, **Ronco PM**. The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. *J Cell Biol*. **1998** Dec 28;143(7):2067-79.
348. Messiaen T, M'bappé P, Boffa JJ, Khayat R, Mougnot B, Rossert J, **Ronco P**. MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. *Am J Kidney Dis*. **1998** Nov;32(5):E6.
349. Lelongt B, Legallicier B, **Ronco P**. Bases moléculaires du développement rénal [Molecular basis of renal development]. *Nephrologie*. **1998**;19(6):319-27. French.
350. Tattevin P, Messiaen T, Pras V, **Ronco P**, Biour M. Confusion and general seizures following ciprofloxacin administration. *Nephrol Dial Transplant*. **1998** Oct;13(10):2712-3.
351. **Ronco P**, Rossert J, Terzi F, Friedlander G. La progression de l'insuffisance rénale chronique [Progression of chronic renal insufficiency]. *Rev Prat*. **1998** Feb 1;48(3):241-7. French.
352. Bouiller M, Flamant M, Dautheville S, Tassart M, **Ronco P**, Rossert J, Boudghene F. Utilisation du Gadolinium comme produit de contraste au cours d'une angioplastie des artères rénales [Use of Gadolinium as a contrast agent in the course of renal arterial angioplasty]. *J Mal Vasc*. **1998** Jun;23(3):201-3. French.
353. Rougier JP, Guia S, Hagège J, Nguyen G, **Ronco PM**. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1. *Kidney Int*. **1998** Jul;54(1):87-98.

354. Guerra L, Di Sole F, Valenti G, **Ronco PM**, Perlino E, Casavola V, Reshkin SJ. Polarized distribution of Na<sup>+</sup>/H<sup>+</sup> exchanger isoforms in rabbit collecting duct cells. *Kidney Int.* **1998** May;53(5):1269-77.
355. Messiaen T, **Ronco P**, Rossert J. Glomérulopathies médicamenteuses [Drug- induced glomerulopathies]. *Nephrologie.* **1998**;19(1):7-10. French.

## 1997

356. Messiaen TG, Plaisier EM, Rossert J, Mougnot B, Bakouche P, **Ronco PM**. Heavy proteinuria, podocyte hypertrophy and severe systemic manifestations in a patient on phenytoin therapy. *Nephrol Dial Transplant.* **1997** Dec;12(12):2723-5.
357. Chailley-Heu B, Rubio S, Rougier JP, Ducroc R, Barlier-Mur AM, **Ronco P**, Bourbon JR. Expression of hydrophilic surfactant proteins by mesentery cells in rat and man. *Biochem J.* **1997** Nov 15;328 ( Pt 1)(Pt 1):251-6.
358. Plaisier EM, Mougnot B, Khayat R, Gattegno B, Mignon F, **Ronco PM**. Ureteral stenosis in Wegener's granulomatosis. *Nephrol Dial Transplant.* **1997** Aug;12(8):1759-61.
359. Sibilia J, Benlagha K, Vanhille P, **Ronco P**, Brouet JC, Mariette X. Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis. *J Immunol.* **1997** Jul 15;159(2):712-9.
360. Lelongt B, Trugnan G, Murphy G, **Ronco PM**. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. *J Cell Biol.* **1997** Mar 24;136(6):1363-73.
361. Le Panse S, Ayani E, Nielsen S, **Ronco P**, Verroust P, Christensen EI. Internalization and recycling of glycoprotein 280 in epithelial cells of yolk sac. *Eur J Cell Biol.* **1997** Mar;72(3):257-67.
362. Magdelaine A, Akposso K, Verdy E, Noc V, Peraldi MN, **Ronco P**, Rondeau E. Does the Q506 mutation of factor V contribute to thrombotic events in the nephrotic syndrome? *Thromb Haemost.* **1997** Mar;77(3):600.
363. Le Goas F, May P, **Ronco P**, Caron de Fromental C. cDNA cloning and immunological characterization of rabbit p53. *Gene.* **1997** Feb 7;185(2):169-73.
364. Moullier P, Salvetti A, Champion-Arnaud P, **Ronco PM**. Gene transfer into the kidney: current status and limitations. *Nephron.* **1997**;77(2):139-51.
365. Guella A, Akhtar M, **Ronco P**. Idiopathic membranous nephropathy in identical twins. *Am J Kidney Dis.* **1997** Jan;29(1):115-8.
366. Rougier JP, Moullier P, Piedagnel R, **Ronco PM**. Hyperosmolality suppresses but TGF beta 1 increases MMP9 in human peritoneal mesothelial cells. *Kidney Int.* **1997** Jan;51(1):337-47.
367. Millul V, Ardaillou N, Placier S, Baudouin B, **Ronco PM**. Receptors for natriuretic peptides in a human cortical collecting duct cell line. *Kidney Int.* **1997** Jan;51(1):281-7.
368. Xu Y, Olives B, Bailly P, Fischer E, Ripoché P, **Ronco P**, Cartron JP, Rondeau E. Endothelial cells of the kidney vasa recta express the urea transporter HUT11. *Kidney Int.* **1997** Jan;51(1):138-46.

## 1996

369. Valenti G, Frigeri A, **Ronco PM**, D'Ettorre C, Svelto M. Expression and functional analysis of water channels in a stably AQP2-transfected human collecting duct cell line. *J Biol Chem.* **1996** Oct 4;271(40):24365-70.
370. Czekalski S, Chansel D, Vandermeersch S, **Ronco P**, Ardaillou R. Evidence for angiotensin IV receptors in human collecting duct cells. *Kidney Int.* **1996** Oct;50(4):1125-31.
371. Millul V, Prié D, Géniteau-Legendre M, Verpont MC, Baudouin B, **Ronco PM**. ANP-stimulated cGMP egression in renal principal cells: abrogation of polarity by SV40 large T. *Am J Physiol.* **1996** Apr;270(4 Pt 1):C1051-60.
372. Plaisier EM, Legallier B, Faintuch JM, **Ronco PM**. Acute portal vein thrombosis at the onset of a nephrotic syndrome. *Nephrol Dial Transplant.* **1996** Apr;11(4):696-8.
373. Schuster VL, Lu R, Kanai N, Bao Y, Rosenberg S, Prié D, **Ronco P**, Jennings ML. Cloning of the rabbit homologue of mouse 'basigin' and rat 'OX-47': kidney cell type-specific expression, and regulation in collecting duct cells. *Biochim Biophys Acta.* **1996** Mar 27;1311(1):13-9.
374. Cittanova ML, Lelongt B, Verpont MC, Geniteau-Legendre M, Wahbe F, Prié D, Coriat P, **Ronco PM**. Fluoride ion toxicity in human kidney collecting duct cells. *Anesthesiology.* **1996** Feb;84(2):428-35.
375. **Ronco P**, Rondeau E, Sraer JD. Pompes, canaux et transporteurs du tubule rénal: un champ d'exploration en plein développement [Pumps, channels and transporters of the renal tubule: a growing field of investigation]. *Nephrologie.* **1996**;17(7):345. French.

## 1995

376. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, **Ronco P**, Remuzzi G. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. *Am J Kidney Dis.* **1995** Dec;26(6):934-41.
377. Bensoussan M, Heudes D, Nahmias C, Delauche M, Lelongt B, **Ronco PM**. Organ culture of rat kidney: a model for angiotensin II receptor ontogenic studies. *Kidney Int.* **1995** Nov;48(5):1635-40.
378. Rocca A, Khamlichi AA, Touchard G, Mougnot B, **Ronco P**, Denoroy L, Deret S, Preud'homme JL, Aucouturier P, Cogné M. Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome. *J Immunol.* **1995** Sep 15;155(6):3245-52.
379. Awdeh ZL, Alper CA, Fici DA, **Ronco P** 2nd, Yunis EJ. Predictability of alloreactivity among unrelated individuals: role for HLA-DPB1. *Tissue Antigens.* **1995** Sep;46(3 ( Pt 1)):180-6.
380. Baricault L, Galceran M, **Ronco PM**, Trugnan G, Verroust PJ. Unusual processing of GP280, a protein associated with the intermicrovillar areas of yolk sac epithelial cells: plasma membrane delivery of immature protein. *Biochem Biophys Res Commun.* **1995** Jul 17;212(2):353-9.
381. Leboulleux M, Lelongt B, Mougnot B, Touchard G, Makdassi R, Rocca A, Noel LH, **Ronco PM**, Aucouturier P. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. *Kidney Int.* **1995** Jul;48(1):72-9.
382. Le Panse S, Galceran M, Pontillon F, Lelongt B, van de Putte M, **Ronco PM**, Verroust PJ. Immunofunctional properties of a yolk sac epithelial cell line expressing two proteins gp280 and gp330 of the intermicrovillar area of proximal tubule cells: inhibition of endocytosis by the specific antibodies. *Eur J Cell Biol.* **1995** Jun;67(2):120-9.



383. Fischer E, Schnermann J, Briggs JP, Kriz W, **Ronco PM**, Bachmann S. Ontogeny of NO synthase and renin in juxtaglomerular apparatus of rat kidneys. *Am J Physiol.* **1995** Jun;268(6 Pt 2):F1164-76.
384. Prié D, Friedlander G, Coureau C, Vandewalle A, Cassingéna R, **Ronco PM**. Role of adenosine on glucagon-induced cAMP in a human cortical collecting duct cell line. *Kidney Int.* **1995** May;47(5):1310-8.
385. Christensen EI, Nielsen S, Moestrup SK, Borre C, Maunsbach AB, de Heer E, **Ronco P**, Hammond TG, Verroust P. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. *Eur J Cell Biol.* **1995** Apr;66(4):349-64.
386. **Ronco PM**, Mougénot B, Touchard G, Preud'homme JL, Aucouturier P. Renal involvement in hematological disorders: monoclonal immunoglobulins and nephropathy. *Curr Opin Nephrol Hypertens.* **1995** Mar;4(2):130-8.
387. Aucouturier P, **Ronco P**. New insights into the mechanisms of myeloma- associated renal diseases. *Ann Med Interne (Paris).* **1995**;146(5):290-1.

## 1994

388. **Ronco PM**, Flahault A. Drug-induced end-stage renal disease. *N Engl J Med.* **1994** Dec 22;331(25):1711-2.
389. Le Panse S, Ayani E, Mulliez N, Chatelet F, Cywiner-Golenz C, Galceran M, Citadelle D, Roux C, **Ronco P**, Verroust P. Antibodies to the 280-kd coated pit protein, target of teratogenic antibodies, produce alterations in the traffic of internalized proteins. *Am J Pathol.* **1994** Dec;145(6):1526-36.
390. Teulon J, **Ronco PM**, Vandewalle A. Renal cells transformed with SV40 contain a high-conductance calcium-insensitive potassium channel. *Am J Physiol.* **1994** Oct;267(4 Pt 1):C940-5.
391. Piédagnel R, Prié D, Cassingéna R, **Ronco PM**, Lelongt B. SV40 large-T oncogene inhibits transcription of perlecan-related proteoglycans but stimulates hyaluronan synthesis in a temperature-sensitive renal-tubule principal cell line. *J Biol Chem.* **1994** Jul 1;269(26):17469-76.
392. Prie D, Dussaule JC, Lelongt B, Geniteau-Legendre M, Chatelet F, Cassingéna R, Vandewalle A, **Ronco PM**. Principal cell-specific antigen and hormonal regulatory network in RC.SVtsA58 cell line. *Am J Physiol.* **1994** Jun;266(6 Pt 1):C1628-38.
393. Moullier P, Friedlander G, Calise D, **Ronco P**, Perricaudet M, Ferry N. Adenoviral-mediated gene transfer to renal tubular cells in vivo. *Kidney Int.* **1994** Apr;45(4):1220-5.
394. **Ronco PM**, Ardaillou N, Verroust P, Lelongt B. Pathophysiology of the podocyte: a target and a major player in glomerulonephritis. *Adv Nephrol Necker Hosp.* **1994**;23:91-131.
395. Rougier JP, Viron B, **Ronco P**, Khayat R, Michel C, Mignon F. Autoimmune haemolytic anaemia after ABO-match, ABDR full match kidney transplantation. *Nephrol Dial Transplant.* **1994**;9(6):693-7.

## 1993

396. Stefanovic V, Ardaillou N, Vlahovic P, Placier S, **Ronco P**, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. *Immunology.* **1993** Nov;80(3):465-70.
397. Bensoussan M, Mitchell T, Reilly T, Timmermans PB, Verroust PJ, **Ronco PM**. Immunological reactivity of angiotensin II receptor antagonists: possible implications for receptor binding sites. *Eur J Pharmacol.* **1993** Oct 15;247(2):169-75.
398. Vandewalle A, Rafestin-Oblin ME, Hagege J, Géniteau-Legendre M, Cassingéna R, **Ronco PM**. Phenotypic effects of aldosterone and dexamethasone in a SV40-transformed mammalian cortical ascending limb cell line exhibiting mineralocorticoid receptors. *J Cell Physiol.* **1993** Aug;156(2):383-94.
399. Ardaillou N, Placier S, Wahbe F, **Ronco P**, Ardaillou R. Release of cyclic nucleotides from the apical and basolateral poles of cultured human glomerular epithelial cells. *Exp Nephrol.* **1993** Jul-Aug;1(4):253-60.
400. Debiec H, **Ronco PM**. Identification and epitope analysis of the renal Na<sup>+</sup>/Pi cotransport protein using monoclonal antibodies. *J Biol Chem.* **1993** Jun 25;268(18):13356-63.
401. Sahali D, Mulliez N, Chatelet F, Laurent-Winter C, Citadelle D, Sabourin JC, Roux C, **Ronco P**, Verroust P. Comparative immunochemistry and ontogeny of two closely related coated pit proteins. The 280-kd target of teratogenic antibodies and the 330-kd target of nephritogenic antibodies. *Am J Pathol.* **1993** May;142(5):1654-67.
402. Verroust P, Mulliez N, Chatelet F, Sahali D, **Ronco P**, Roux C. Tératogénèse et auto-immunité: signification en pathologie humaine d'un modèle expérimental murin [Teratogenesis and autoimmunity: significance of an experimental murine model for human pathology]. *Bull Acad Natl Med.* **1993** Apr;177(4):613-26; discussion 626-7. French.
403. Vandewalle A, Vuillemin T, Teulon J, Baudouin B, Wahbe F, Bens M, Cassingéna R, **Ronco P**. K<sup>+</sup> fluxes mediated by Na<sup>+</sup>-K<sup>+</sup>-Cl<sup>-</sup> cotransport and Na<sup>+</sup>-K<sup>+</sup>-ATPase pumps in renal tubule cell lines transformed by wild-type and temperature-sensitive strains of Simian virus 40. *J Cell Physiol.* **1993** Mar;154(3):466-77.
404. **Ronco P**, Mougénot B, Bindi P, Noel LH, Mignon F, Lesavre P. Les glomérulonéphrites extracapillaires "idiopathiques" sans dépôt immun sont des vascularites: analyse clinique et sérologique ["Idiopathic" extracapillary glomerulonephritides without immune deposits are vascularities: clinical and serologic analysis]. *Bull Acad Natl Med.* **1993** Mar;177(3):481-94; discussion 494-8. French.
405. Van Leer EH, **Ronco P**, Verroust P, van der Wal AM, Hoedemaeker PJ, De Heer E. Epitope specificity of anti-gp330 autoantibodies determines the development of proteinuria in active Heymann nephritis. *Am J Pathol.* **1993** Mar;142(3):821-9.
406. Le Goas F, Mougénot B, Mignon F, **Ronco P**. Complications rénales tubulo- interstitielles du myélome [Tubulo-interstitial renal complications of myeloma]. *Rev Prat.* **1993** Feb 1;43(3):307-13. French.
407. Bindi P, Mougénot B, Mentre F, Peraldi MN, Vanhille P, Lesavre P, Mignon F, **Ronco PM**. Necrotizing crescentic glomerulonephritis without significant immune deposits: a clinical and serological study. *Q J Med.* **1993** Jan;86(1):55-68.
408. Dussaule JC, Stefanski A, Béa ML, **Ronco P**, Ardaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. *Am J Physiol.* **1993** Jan;264(1 Pt 2):F45-52.
409. Lelongt B, Vandewalle A, Brechley PE, Baudouin B, Géniteau-Legendre M, Verroust PJ, **Ronco PM**. Major influence of cell differentiation status on characteristics of proteoglycans synthesized by cultured rabbit renal proximal tubule cells: role of insulin and dexamethasone. *J Cell Physiol.* **1993** Jan;154(1):175-91.
410. Meulders Q, Viron B, Michel C, Mougénot B, Antoine M, Meyohas MC, **Ronco P**, Mignon F. Burkitt's lymphoma of the kidney presenting as acute renal failure in AIDS. *Nephrol Dial Transplant.* **1993**;8(5):458-60.

411. Rafestin-Oblin ME, Farman N, Cassingena R, **Ronco P**, Vandewalle A. Mineralocorticoid receptors in SV40-transformed tubule cell lines derived from rabbit kidney. *J Steroid Biochem Mol Biol*. **1993** Jan;44(1):45-52.
412. Lamriben L, Kourilsky O, Mougenot B, **Ronco P**, Sraer JD. Goodpasture's syndrome with asymptomatic renal involvement. Disappearance of anti-glomerular basement membrane antibodies deposits after treatment. *Nephrol Dial Transplant*. **1993**;8(11):1267-9.

## 1992

413. Lelongt B, Piedagnel R, Châtelet F, Baudouin B, Brenchley PE, Verroust PJ, Cassingena R, Vandewalle A, **Ronco PM**. Dramatic changes of sulfated proteoglycans composition in a tumorigenic SV-40-transformed renal proximal-tubule cell line. *J Biol Chem*. **1992** Nov 25;267(33):23815-22.
414. Kadereit S, Michelson S, Mougenot B, Thibault P, Verroust PJ, Mignon F, Colimon R, **Ronco PM**. Polymerase chain reaction detection of cytomegalovirus genome in renal biopsies. *Kidney Int*. **1992** Oct;42(4):1012-6.
415. Ardaillou N, Lelongt B, Turner N, Piedagnel R, Baudouin B, Estrade S, Cassingena R, **Ronco PM**. Characterization of a simian virus 40-transformed human podocyte cell line producing type IV collagen and exhibiting polarized response to atrial natriuretic peptide. *J Cell Physiol*. **1992** Sep;152(3):599-616.
416. Vuillemin T, Teulon J, Geniteau-Legendre M, Baudouin B, Estrade S, Cassingena R, **Ronco P**, Vandewalle A. Regulation by calcitonin of Na(+)-K(+)-Cl- cotransport in a rabbit thick ascending limb cell line. *Am J Physiol*. **1992** Sep;263(3 Pt 1):C563-72.
417. Debiec H, Lorenc R, **Ronco PM**. Reconstitution and characterization of a Na+/Pi co-transporter protein from rabbit kidney brush-border membranes. *Biochem J*. **1992** Aug 15;286 ( Pt 1)(Pt 1):97-102.
418. Garcia KC, Desiderio SV, **Ronco PM**, Verroust PJ, Amzel LM. Recognition of angiotensin II: antibodies at different levels of an idiotypic network are superimposable. *Science*. **1992** Jul 24;257(5069):528-31.
419. Garcia KC, **Ronco PM**, Verroust PJ, Brünner AT, Amzel LM. Three-dimensional structure of an angiotensin II-Fab complex at 3 Å: hormone recognition by an anti-idiotypic antibody. *Science*. **1992** Jul 24;257(5069):502-7.
420. Moulin B, **Ronco PM**, Mougenot B, Francois A, Fillastre JP, Mignon F. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. *Kidney Int*. **1992** Jul;42(1):127-35.
421. Ardaillou R, Dussaule JC, Chansel D, Prie D, Ardaillou N, **Ronco P**. Mode d'action et catabolisme du facteur auriculaire natriurétique dans les cellules rénales humaines et animales en culture [Mechanism of action and catabolism of atrial natriuretic factor in cultured human and animal kidney cells]. *Bull Acad Natl Med*. **1992** Jun;176(6):769-81; discussion 781-2. French.
422. Stefanovic V, Vlahovic P, Ardaillou N, **Ronco P**, Ardaillou R. Cell surface aminopeptidase A and N activities in human glomerular epithelial cells. *Kidney Int*. **1992** Jun;41(6):1571-80.
423. Meulders Q, Michel C, Marteau P, Grange JD, Mougenot B, **Ronco P**, Mignon F. Association of chronic interstitial cystitis, protein-losing enteropathy and paralytic ileus with seronegative systemic lupus erythematosus: case report and review of the literature. *Clin Nephrol*. **1992** May;37(5):239-44.
424. Budisavljevic M, Béa ML, Bensoussan M, Laubie M, Van Chuong PP, Dussaule JC, Verroust PJ, **Ronco PM**. Antagonist effect of a receptor-mimicking peptide encoded by human angiotensin II complementary RNA. *Hypertension*. **1992** Apr;19(4):345-54.
425. Teulon J, **Ronco PM**, Geniteau-Legendre M, Baudouin B, Estrade S, Cassingena R, Vandewalle A. Transformation of renal tubule epithelial cells by simian virus-40 is associated with emergence of Ca(2+)-insensitive K+ channels and altered mitogenic sensitivity to K+ channel blockers. *J Cell Physiol*. **1992** Apr;151(1):113-25.
426. Sahali D, Mulliez N, Chatelet F, Laurent-Winter C, Citadelle D, Roux C, **Ronco P**, Verroust P. Coexpression in humans by kidney and fetal envelopes of a 280 kDa-coated pit-restricted protein. Similarity with the murine target of teratogenic antibodies. *Am J Pathol*. **1992** Jan;140(1):33-44.
427. Monod L, Hamou MF, Verroust P, de Tribolet N. Expression of cALLa/NEP on gliomas: a possible marker of malignancy. *Acta Neurochir (Wien)*. **1992**;114(1-2):3-7.
428. **Ronco PM**. Faut-il traiter les glomérulonéphrites extramembraneuses idiopathiques? Vers une approche "moléculaire" des indications thérapeutiques [Should idiopathic extramembranous glomerulonephritis be treated? Toward a "molecular" approach of therapeutic indications]. *Nephrologie*. **1992**;13(5):189-91. French.
429. **Ronco P**, Sahali D, Cittanova ML, van Leer EH, Chatelet F, Verroust P. Monoclonal antibodies to glomerular antigens. *Nephrol Dial Transplant*. **1992**;7 Suppl 1:9-15.
430. van Leer EH, **Ronco P**, Verroust P, de Roo GM, Hoedemaeker PJ, de Heer E. Heymann nephritis: a model of human membranous glomerulopathy. A study of the role of additional antigens. *Nephrol Dial Transplant*. **1992**;7 Suppl 1:1-8.
431. Bindi P, Mougenot B, Mentre F, Noël LH, Lesavre P, Mignon F, **Ronco P**. Glomérulonéphrites extra-capillaires et nécrosantes sans dépôts d'immunoglobuline: aspects cliniques et nosologiques [Extracapillary and necrotizing glomerulonephritis without immunoglobulin deposits: clinical and nosological aspects]. *Nephrologie*. **1992**;13(6):287-90. French.
432. Michel C, Dosquet P, **Ronco P**, Mougenot B, Viron B, Mignon F. Nephropathy associated with infection by human immunodeficiency virus: a report on 11 cases including 6 treated with zidovudine. *Nephron*. **1992**;62(4):434-40.
433. Suc JM, **Ronco P**. Les glomérulonéphrites rapidement progressives (GNRP): des croissants à l'activation des polynucléaires [Rapidly progressive glomerulonephritis (RPGN): from crescents to polynuclear activation]. *Nephrologie*. **1992**;13(6):241-2. French.

## 1991

434. Bindi P, Mougenot B, Mentre F, Noël LH, Peraldi MN, Vanhille P, Lesavre P, Mignon F, **Ronco P**. Glomérulonéphrite extracapillaire nécrosante sans dépôts d'immunoglobuline. Localisation rénale d'une vasculite systémique avec anticorps anti-cytoplasme des polynucléaires [Necrotizing extracapillary glomerulonephritis without immunoglobulin deposits. Renal localization of systemic vasculitis with anti-cytoplasm polynuclear antibodies]. *Presse Med*. **1991** Nov 23;20(39):1939-43. French.
435. **Ronco P**, Verroust P, Chatelet F. Apports de la pathologie expérimentale à la compréhension des glomérulonéphrites immunologiques humaines [Contribution of experimental pathology to the understanding of human immune glomerulonephritis]. *Rev Prat*. **1991** Nov 15;41(24):2411-8. French.

436. Michel C, Dosquet P, Viron B, Meyohas MC, **Ronco P**, Mignon F. Néphropathie associée à l'infection par le virus de l'immunodéficience humaine: intérêt thérapeutique possible de la zidovudine [Nephropathy associated with human immunodeficiency virus infection: possible therapeutic value of zidovudine]. *Presse Med.* **1991** Nov 9;20(36):1785-6. French.
437. Pollard H, Moreau J, **Ronco P**, Verroust P, Schwartz JC. Immunoautoradiographic localisation of enkephalinase (EC 3.4.24.11) in rat gastrointestinal tract. *Neuropeptides.* **1991** Jul;19(3):169-78.
438. Vandewalle A, **Ronco P**, Cassingena R. Establishment of permanent renal tubule cell lines by infection with the wild-type and a thermosensitive mutant of the simian virus 40. *Am J Kidney Dis.* **1991** Jun;17(6):619-21.
439. Prié D, **Ronco PM**, Baudouin B, Géniteau-Legendre M, Antoine M, Piedagnel R, Estrade S, Lelongt B, Verroust PJ, Cassingena R, et al. Activation of the simian virus 40 (SV40) genome abrogates sensitivity to AVP in a rabbit collecting tubule cell line by repressing membrane expression of AVP receptors. *J Cell Biol.* **1991** May;113(4):951-62.
440. Kettani S, Beldent V, Rousselet MC, **Ronco P**, Verroust P, Saint-Andre JP. Presence of renin, angiotensinogen, angiotensin II in the lamb anterior pituitary gland: immunocytochemical study after cryoultramicrotomy. *Histochemistry.* **1991**;95(6):561-6.
441. **Ronco P**, Mougnot B, Bindi P, Vanhille P, Mignon F. Clinico-histological features and long-term outcome of Wegener's granulomatosis. *Contrib Nephrol.* **1991**;94:47-57.

## 1990

442. Guillevin L, **Ronco P**, Verroust P. Circulating immune complexes in systemic necrotizing vasculitis of the polyarteritis nodosa group. Comparison of HBV-related polyarteritis nodosa and Churg Strauss Angiitis. *J Autoimmun.* **1990** Dec;3(6):789-92.
443. **Ronco P**, Antoine M, Baudouin B, Geniteau-Legendre M, Lelongt B, Chatelet F, Verroust P, Vandewalle A. Polarized membrane expression of brush-border hydrolases in primary cultures of kidney proximal tubular cells depends on cell differentiation and is induced by dexamethasone. *J Cell Physiol.* **1990** Nov;145(2):222-37.
444. Gaulier A, Lucas G, **Ronco P**. Tamm Horsfall protein expression by a small renal cell carcinoma presenting with metastases. *Histopathology.* **1990** Nov;17(5):451-5.
445. Budisavljevic M, **Ronco PM**, Verroust PJ. Angiotensin II (AII)-related idiotype network. III. Comparative analysis of idiotopes and paratopes borne by monoclonal antibodies raised against AII (AB1) and its internal image (AB3). *J Immunol.* **1990** Sep 1;145(5):1440-9.
446. Zenklusen C, Meyer O, Le Ti Huong Du Z, Gaudouen C, **Ronco P**, Mery JP, Kahn MF. Intérêt des anticorps anti-cytoplasme de polynucléaires dans le diagnostic et le suivi de la maladie de Wegener et d'autres vascularites systémiques [Anticytoplasmic antibodies of polynuclears in the diagnosis and follow-up of Wegener's disease and other systemic vasculitis]. *Rev Rhum Mal Osteoartic.* **1990** Jan;57(1):47-51. French.
447. Allegri L, Celendo MT, Ferrari C, Savazzi G, **Ronco P**, Verroust P. Role of a 90-kD glycoprotein in Heymann's nephritis. *Nephrol Dial Transplant.* **1990**;5 Suppl 1:60-2.
448. Rife G, **Ronco P**. Pour ou contre la biopsie rénale après 65 ans [For or against renal biopsy after 65 years]. *Nephrologie.* **1990**;11(5):301-6. French.

## 1989

449. Garcia KC, **Ronco P**, Verroust PJ, Amzel LM. Crystallization and preliminary X-ray diffraction data of an anti-angiotensin II Fab and of the peptide-Fab complex. *J Biol Chem.* **1989** Dec 5;264(34):20463-6.
450. Monod L, Diserens AC, Jongeneel CV, Carrel S, **Ronco P**, Verroust P, de Tribolet N. Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity. *Int J Cancer.* **1989** Nov 15;44(5):948-51.
451. Vandewalle A, Lelongt B, Geniteau-Legendre M, Baudouin B, Antoine M, Estrade S, Chatelet F, Verroust P, Cassingena R, **Ronco P**. Maintenance of proximal and distal cell functions in SV40-transformed tubular cell lines derived from rabbit kidney cortex. *J Cell Physiol.* **1989** Oct;141(1):203-21.
452. Dussaule JC, Béa ML, Baud L, **Ronco P**, Chansel D, Helwig JJ, Ardaillou R. Effects of bradykinin on prostaglandin synthesis and cytosolic calcium in rabbit subcultured renal cortical smooth muscle cells. *Biochim Biophys Acta.* **1989** Sep 11;1005(1):34-44.
453. **Ronco P**, Mougnot B, Kanfer A, Verroust P, Mignon F. Atteintes rénales des angéites nécrosantes [Renal involvement in necrotizing angiitis]. *Rev Med Interne.* **1989** May-Jun;10(3):227-34. French.
454. Fievet P, Boudjelal M, Demontis R, Veyssier P, Lallement PY, Bove N, **Ronco P**. Hemorrhagic fever with renal syndrome and Tamm-Horsfall protein. *Ann Intern Med.* **1989** Feb 15;110(4):325.
455. Jongeneel CV, Quackenbush EJ, **Ronco P**, Verroust P, Carrel S, Letarte M. Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity. *J Clin Invest.* **1989** Feb;83(2):713-7.
456. Verroust P, **Ronco P**. Formation des dépôts immuns au cours des glomérulonéphrites extramembraneuses expérimentales [Formation of immune deposits during experimental extramembranous glomerulonephritis]. *Nephrologie.* **1989**;10(3):123-6. French.
457. Rossert J, Rondeau E, Jondeau G, **Ronco P**, Mougnot B, Kanfer A, Sraer JD. Tamm-Horsfall protein accumulation in glomeruli during acetazolamide-induced acute renal failure. *Am J Nephrol.* **1989**;9(1):56-7.
458. Assmann KJ, **Ronco P**, Tangelder MM, Lange WP, Verroust P, Koene RA. Involvement of an antigen distinct from the Heymann antigen in membranous glomerulonephritis in the mouse. *Lab Invest.* **1989** Jan;60(1):138-46.
459. **Ronco P**, Allegri L, Brianti E, Chatelet F, Van Leer EH, Verroust P. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. *Appl Pathol.* **1989**;7(2):85-98.
460. Pollard H, Bouthenet ML, Moreau J, Souil E, Verroust P, **Ronco P**, Schwartz JC. Detailed immunoautoradiographic mapping of enkephalinase (EC 3.4.24.11) in rat central nervous system: comparison with enkephalins and substance P. *Neuroscience.* **1989**;30(2):339-76.

## 1988

461. **Ronco P**, Allegril, Brianti E, Chatelet F, Van Leer EH, Veroust P, Richet G. Antigenic targets in membranous glomerulonephritis. *Pol Arch Med Wewn*. **1988** Oct;80(4):178-88.
462. **Ronco P**, Dosquet P, Verroust P. La protéine de Tamm-Horsfall [Tamm-Horsfall protein]. *Presse Med*. **1988** Sep 24;17(32):1641-6. French.
463. Moulin B, Sahali D, Baud L, Toussaint P, Michel C, **Ronco P**, Mignon F. Gallium67 scintigraphy in the diagnosis of glomerulonephritis. *Clin Nephrol*. **1988** Sep;30(3):128-33.
464. Tauc M, Chatelet F, Verroust P, Vandewalle A, Poujeol P, **Ronco P**. Characterization of monoclonal antibodies specific for rabbit renal brush-border hydrolases: application to immunohistological localization. *J Histochem Cytochem*. **1988** May;36(5):523-32.
465. Budisavljevic M, Geniteau-Legendre M, Baudouin B, Pontillon F, Verroust PJ, **Ronco PM**. Angiotensin II (All)-related idiotypic network. II. Heterogeneity and fine specificity of All internal images analyzed with monoclonal antibodies. *J Immunol*. **1988** May 1;140(9):3059-65.
466. Pontillon F, Moullier P, **Ronco PM**, Verroust PJ. Angiotensin II (All)-related idiotypic network. I. Common occurrence of All internal image on rabbit anti- idiotypic antibodies. *J Immunol*. **1988** May 1;140(9):3052-8.
467. **Ronco P**, Pollard H, Galceran M, Delauche M, Schwartz JC, Verroust P. Distribution of enkephalinase (membrane metalloendopeptidase, E.C. 3.4.24.11) in rat organs. Detection using a monoclonal antibody. *Lab Invest*. **1988** Feb;58(2):210-7.
468. Michel C, Montravers P, Viron B, **Ronco P**, Lacombe M, Mignon F. Intérêt de la revascularisation rénale dans l'hypertension rénovasculaire avec insuffisance rénale [Value of the kidney revascularization in renovascular hypertension with kidney failure]. *Presse Med*. **1988** Jan 9-16;17(1):9-12. French.
469. Sahali D, Mulliez N, Chatelet F, Dupuis R, **Ronco P**, Verroust P. Characterization of a 280-kD protein restricted to the coated pits of the renal brush border and the epithelial cells of the yolk sac. Teratogenic effect of the specific monoclonal antibodies. *J Exp Med*. **1988** Jan 1;167(1):213-8.

## 1987

470. Pelletier L, Galceran M, Pasquier R, **Ronco P**, Verroust P, Bariety J, Druet P. Down modulation of Heymann's nephritis by mercuric chloride. *Kidney Int*. **1987** Aug;32(2):227-32.
471. Pollard H, Llorens-Cortes C, Couraud JY, **Ronco P**, Verroust P, Schwartz JC. Enkephalinase (EC 3.4.24.11) is highly localized to a striatonigral pathway in rat brain. *Neurosci Lett*. **1987** Jun 26;77(3):267-71.
472. Zoja C, Benigni A, Verroust P, **Ronco P**, Bertani T, Remuzzi G. Indomethacin reduces proteinuria in passive Heymann nephritis in rats. *Kidney Int*. **1987** Jun;31(6):1335-43.
473. Poujeol P, **Ronco P**, Tauc M, Geniteau M, Chatelet F, Sahali D, Vandewalle A, Verroust P. Immunological segmentation of the rabbit distal, connecting, and collecting tubules. *Am J Physiol*. **1987** Mar;252(3 Pt 2):F412-22.
474. Van Leer EH, Moullier P, **Ronco P**, Verroust P. Lymphocyte expression of a 90 kD brush border antigen. *Clin Exp Immunol*. **1987** Mar;67(3):572-80.
475. Pollard H, De la Baume S, Bouthenet ML, Schwartz JC, **Ronco P**, Verroust P. Characterisation of two probes for the localisation of enkephalinase in rat brain: [3H]thiorphan and a 125I-labeled monoclonal antibody. *Eur J Pharmacol*. **1987** Jan 13;133(2):155-64.
476. **Ronco P**, Brunisholz M, Geniteau-Legendre M, Chatelet F, Verroust P, Richet G. Physiopathologic aspects of Tamm-Horsfall protein: a phylogenetically conserved marker of the thick ascending limb of Henle's loop. *Adv Nephrol Necker Hosp*. **1987**;16:231-49.
477. Verroust P, **Ronco P**, Chatelet F. Antigenic targets in membranous glomerulonephritis. *Springer Semin Immunopathol*. **1987**;9(4):341-58.

## 1986

478. Verroust P, **Ronco PM**, Chatelet F. Monoclonal antibodies and identification of glomerular antigens. *Kidney Int*. **1986** Nov;30(5):649-55.
479. Allegril L, Brianti E, Chatelet F, Manara GC, **Ronco P**, Verroust P. Polyvalent antigen-antibody interactions are required for the formation of electron-dense immune deposits in passive Heymann's nephritis. *Am J Pathol*. **1986** Oct;125(1):1-6.
480. Michel C, Montravers P, Viron B, **Ronco P**, Lacombe M, Mignon F. HTA rénovasculaire avec insuffisance rénale: intérêt de la revascularisation rénale [Renovascular hypertension with renal failure: value of renal revascularization]. *Arch Mal Coeur Vaiss*. **1986** Jun;79(6):851-6. French.
481. Brunisholz M, Geniteau-Legendre M, **Ronco PM**, Moullier P, Pontillon F, Richet G, Verroust PJ. Characterization of monoclonal antibodies specific for human Tamm-Horsfall protein. *Kidney Int*. **1986** May;29(5):971-6.
482. Chatelet F, Brianti E, **Ronco P**, Roland J, Verroust P. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. I. Renal distribution. *Am J Pathol*. **1986** Mar;122(3):500-11.
483. Chatelet F, Brianti E, **Ronco P**, Roland J, Verroust P. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. II. Extrarenal distribution. *Am J Pathol*. **1986** Mar;122(3):512-9.
484. Vandewalle A, Tauc M, Cluzeaud F, **Ronco P**, Chatelet F, Verroust P, Poujeol P. Indirect immunoselection of late distal cell populations from rabbit kidney cortex. *Am J Physiol*. **1986** Mar;250(3 Pt 2):F386-95.
485. **Ronco P**, Geniteau M, Poujeol P, Melcion C, Verroust P, Vandewalle A. Characterization of monoclonal antibodies to rabbit renal cortical cells. *Am J Physiol*. **1986** Mar;250(3 Pt 1):C506-16.
486. Gros C, Solhonne B, Giros B, Pollard H, Salès N, Schwartz JC, **Ronco P**, Verroust P. Immunohistochemical and subcellular studies of aminopeptidase M localization in rat brain: microvessels and synaptic membranes. *NIDA Res Monogr*. **1986**;75:303-6.
487. Picard C, **Ronco P**, Moullier P, Yao J, Baudouin B, Geniteau Legendre M, Verroust P. Epitope diversity of angiotensin II analysed with monoclonal antibodies. *Immunology*. **1986** Jan;57(1):19-24.

488. **Ronco P**, Neale TJ, Wilson CB, Galceran M, Verroust P. An immunopathologic study of a 330-kD protein defined by monoclonal antibodies and reactive with anti-RTE alpha 5 antibodies and kidney eluates from active Heymann nephritis. *J Immunol.* **1986** Jan;136(1):125-30.

## 1985

489. Assmann KJ, **Ronco P**, Tangelder MM, Lange WP, Verroust P, Koene RA. Comparison of antigenic targets involved in antibody-mediated membranous glomerulonephritis in the mouse and rat. *Am J Pathol.* **1985** Oct;121(1):112-22.

## 1984

490. Melcion C, Mougnot B, Baudouin B, **Ronco P**, Moulouguet-Doleris L, Vanhille P, Beauvils M, Morel-Maroger L, Verroust P, Richet G. Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains. *Clin Nephrol.* **1984** Sep;22(3):138-43.V
491. **Ronco P**, Melcion C, Geniteau M, Ronco E, Reininger L, Galceran M, Verroust P. Production and characterization of monoclonal antibodies against rat brush border antigens of the proximal convoluted tubule. *Immunology.* **1984** Sep;53(1):87-95.
492. **Ronco P**, Allegri L, Melcion C, Pirotsky E, Appay MD, Bariety J, Pontillon F, Verroust P. A monoclonal antibody to brush border and passive Heymann nephritis. *Clin Exp Immunol.* **1984** Feb;55(2):319-32.
493. Meyrier A, Français P, Lesavre P, Mougnot B, **Ronco P**, Jeanmougin M, Français C. Vasculite urticarienne hypocomplémentémique avec glomérulopathie et veinulite rénale [Hypocomplementemic urticarial vasculitis with glomerulopathy and renal venulitis]. *Nephrologie.* **1984**;5(1):1-7. French.
494. Mignon F, Méry JP, Mougnot B, **Ronco P**, Roland J, Morel-Maroger L. Granulomatous interstitial nephritis. *Adv Nephrol Necker Hosp.* **1984**;13:219-45.

## 1983

495. **Ronco P**, Verroust P, Mignon F, Kourilsky O, Vanhille P, Meyrier A, Mery JP, Morel-Maroger L. Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: a report of 43 patients with 51 renal biopsies. *Q J Med.* **1983** Spring;52(206):212-23.
496. **Ronco P**, Verroust P, Morel-Maroger L. Role of interferon in the genesis of experimental glomerulonephritis in mice. *Contrib Microbiol Immunol.* **1983**;7:73-82.

## 1982

497. Woodrow D, **Ronco P**, Riviere Y, Moss J, Gresser I, Guillon JC, Morel-Maroger L, Sloper JC, Verroust P. Severity of glomerulonephritis induced in different strains of suckling mice by infection with lymphocytic choriomeningitis virus: correlation with amounts of endogenous interferon and circulating immune complexes. *J Pathol.* **1982** Dec;138(4):325-36.
498. Gayraud M, Guillevin L, Bletty O, **Ronco P**, Friocourt L, Godeau P. Hypergammaglobulinémie et gammapathie monoclonale au cours du syndrome de Gougerot-Sjögren. A propos de trois observations [Hypergammaglobulinemia and monoclonal gammopathy in Gougerot-Sjögren syndrome. Three case-reports. [author's transl]]. *Sem Hop.* **1982** May 20;58(20):1242-6. French.
499. Morel-Maroger L, Gresser I, Guillon JC, Verroust P, **Ronco P**, Riviere Y, Woodrow D. Rôle de l'interféron dans le développement des néphrites expérimentales [The role of interferon in the development of experimental nephritis]. *Bull Acad Natl Med.* **1982** Feb;166(2):229-34. French.
500. **Ronco P**, Mignon F, Laneo Y, Roland J, Morel-Maroger L, Gattegno B. Ureteral stenosis in Wegener's granulomatosis. Report of a case. *Nephron.* **1982**;30(3):201-4.
501. **Ronco P**, Verroust P, Morel-Maroger L. Viruses and Glomerulonephritis. *Nephron.* **1982**;31(2):97-102.

## 1981

502. Kourilsky O, Sraer JD, Martinez-Ara J, Tembely H, Verroust P, **Ronco P**, Brault D, Rouquette AM, Egler R, Poyau-Lemaux C, Gerotta I, Richet G. Echange plasmatique par filtration sur membrane. Expérience de l'Hôpital Tenon [Plasma exchange by membrane filtration. Experience of the Tenon Hospital]. *Rev Fr Transfus Immunohematol.* **1981** Dec;24(6):643-55. French.
503. **Ronco P**, Rivière Y, Thoua Y, Bandu MT, Guillon JC, Verroust P, Morel-Maroger L. Lymphocytic choriomeningitis infection in the nude mouse. An immunopathological study. *Immunology.* **1981** Aug;43(4):763-70.
504. **Ronco P**, Wechsler B, Saillant G, Godeau P. Ostéonécrose aseptique au cours de maladies de Behçet traitées par corticoïdes. 4 malades, 8 localisations [Aseptic osteonecrosis during corticosteroid treatment of Behçet's disease (author's transl)]. *Nouv Presse Med.* **1981** May 9;10(21):1707-10. French.
505. Richet G, Kourilsky O, Martinez-Ara J, Sraer JD, Verroust P, **Ronco P**, Morel-Maroger M. Traitement de l'insuffisance rénale aiguë du myélome par le échanges plasmatiques [Management of acute renal insufficiency in myeloma and certain types of glomerulonephritis with plasma exchange]. *Bull Acad Natl Med.* **1981** May;165(5):573-9. French.
506. **Ronco P**, Verroust P, Morel-Maroger L. Néphropathies glomérulaires et infections virales [Glomerular nephropathies and viral infections]. *Nephrologie.* **1981**;2(4):147-52. French.

## 1980

507. Rivière Y, Gresser I, Guillon JC, Bandu MT, **Ronco P**, Morel-Maroger L, Verroust P. Severity of lymphocytic choriomeningitis virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon. *J Exp Med.* **1980** Sep 1;152(3):633-40.
508. **Ronco P**, Woodrow D, Rivière Y, Moss J, Verroust P, Guillon JC, Gresser I, Sloper JC, Morel-Maroger L. Further studies on the inhibition of lymphocytic choriomeningitis-induced glomerulonephritis by antiinterferon globulin. Circulating immune complexes and ultrastructural studies. *Lab Invest.* **1980** Jul;43(1):37-46.

509. Adam C, Thoua Y, **Ronco P**, Verroust P, Tovey M, Morel-Maroger L. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. *Clin Exp Immunol*. **1980** May;40(2):373-82.
510. Mignon F, **Ronco P**, Verroust P, Poupon R, Prud'homme de Saint-Maur P, Morel- Maroger L. Néphropathie et hyperplasie nodulaire régénérative du foie [Nephropathy and nodular regenerative hyperplasia of the liver (author's transl)]. *Nephrologie*. **1980**;1(1):23-6. French.

## **1978**

511. Mayaud C, Bouchoucha S, Ronco P, Duval G. Les insuffisances rénales aiguës au cours des infections suppurées a pyogènes [Acute renal failure during pyogenic suppurated infections]. *Rev Prat*. **1978** Nov 1;28(49):3881-4, 3887-8, 3891. French.